Corporate News
2024
Half-year Results
21 September 2023
Strategic momentum and revenue growth of 29%
Full year revenue guidance of at least £34m
Kooth (AIM: KOO), a global leader in youth digital mental well-being, announces unaudited half year results for the six months ended 30 June 2023. All figures relate to this period unless otherwise stated.
Strategic and post period end highlights
- Transformational US contract win in California, $188m minimum value
- On track for California go-live in January 2024, notably with the Kooth mobile app and hires
- Number one provider of mental health access for children and young people to NHS England
- Significant uptake of Kooth in Pennsylvania pilot, providing access to c.100,000 school students
- Ongoing investment in business development, platform investment and US expansion
Financial Highlights
- Revenues up 29% to £11.7m (2022: £9.0m)
- Annual Recurring Revenue (ARR) up 16% to £21.4m (2022: £18.5m)
- Gross margin of 66.8% (2022: 68.4%)
- Adjusted EBITDA of £0.01m (2022: £0.5m) reflecting investment in US setup and business development
- Recurring Revenue from contracts 12 months or longer 94% (2022: 95%)
- Robust balance sheet; net cash of £5.9m plus successful gross fundraise of £10m post half-year end supports investment for long-term growth
Outlook
- Significant opportunity for Kooth in the US driven by the continued need from both US State governments and Medicaid payers to invest further in youth mental health
- For the UK, we expect the headwinds to remain, reflecting a focus on NHS cost saving and acute care backlog. Our focus remains on continuing to demonstrate the impact and savings that Kooth generates when commissioned in a region
- The Group remains confident of delivering revenue for the full year in line with our revised market guidance of no less than £34 million
- Our robust balance sheet enables us to invest to meet long-term, increasing demand for Kooth's services
Tim Barker, Chief Executive Officer of Kooth, said:
The first six months of 2023 have been a period of significant, and positive, change for Kooth. In March we announced our largest contract to date with the State of California which was finalised, post-period end, as a four year, $188m minimum value agreement. This marked Kooth's second major engagement in the US, alongside Pennsylvania, which was agreed in October 2022. During the period, and over the last 12 months, we have developed a significant operation in the United States as we look to capture the opportunity this major healthcare market brings. We look forward to leveraging our platform to increase the size of our business further and, more importantly, help improve mental health provision to as many young people as possible.
In the UK, we are not immune to the broader healthcare and economic environment, which sees commissioning across the NHS structure under stress as Integrated Care Systems prioritise a reduction in costs and tackling an acute mental healthcare backlog. In response, we have taken proactive steps to position ourselves to best respond to this environment, including developing new services to help tackle waiting lists.
I would like to thank our team for their work which has delivered transformational gains during the period and beyond as we look to leverage our position as a pioneer and innovator in digital mental healthcare to deliver the care needed to help tackle the growing crisis in global mental health.
Financial headlines
Six months ended 30 June 2023 | Six months ended 30 June 2022 | Change | |||
£'000 | £'000 | ||||
Revenue | |||||
Total revenue | 11,660 | 9,022 | +29.2% | ||
Annual Recurring Revenue | 21,376 | 18,483 | +15.7% | ||
Gross profit | 7,788 | 6,170 | +26.2% | ||
Gross margin | 66.8% | 68.4% | -2.3ppt | ||
Adjusted EBITDA | 9 | 539 | -98.3% | ||
Profit/(Loss) after tax for the period | (525) | (342) | -53.5% | ||
Cash generation | (2,642) | 1,231 | -314.6% | ||
Cash position | 5,850 | 8,310 | -29.6% | ||
Earnings per share (£) | (0.02) | (0.01) | -58.8% |
Enquiries Kooth plc | |
Tim Barker, CEO | |
Panmure Gordon, Nominated Adviser and Joint Broker | +44 (0) 20 7886 2500 |
Stifel Nicolaus Europe Limited, Joint Broker | +44 (0) 20 7710 7600 |
FTI Consulting |
About Kooth
Kooth (AIM:KOO) is a global leader in youth digital mental well-being. Our mission is to provide accessible and safe spaces for everyone to achieve better mental health. Our platform is clinically robust and accredited to provide a range of therapeutic support and interventions. All our services are predicated on easy access to make early intervention and prevention a reality.
Our three services are:
- Kooth: for children and young people
- Kooth: for adults
- Kooth Work: for frontline employees
Kooth is a fully safeguarded and pre-moderated community with a library of peer and professional created content, alongside access to experienced online counsellors. There are no thresholds for support and no waiting lists. Currently, Kooth sees more than 4,000 logins a day.
Kooth is the only digital mental health provider to hold a UK-wide accreditation from the British Association of Counselling and Psychotherapy (BACP) and according to NHS England data for 2021/22 is now the largest single access provider for mental health support for under 18s.
In 2021, Kooth began executing on its international expansion strategy, with an initial focus on the US market. This focus is due to the growing recognition of the importance of improving youth mental health in this key global healthcare market, with 1-in-6 people aged 6-17 experiencing a mental health disorder each year. Kooth's first major pilot contract in the US was signed in October 2022 with the State of Pennsylvania followed in July 2023 by a four-year contract to cover all six million 13-25 year-olds in the State of California.
Chief Executive's Review
Transformational strategic progress
With the award of a $188m four-year state-wide contract with California, the last six months demonstrate the significant opportunity for Kooth in the US as federal and state governments invest to transform youth mental health care.
As one of the work streams within the State of California's $4.7 billion youth masterplan, this investment arguably represents the world's most progressive initiative to improve youth mental health. This was evident at the September UN Congress General Assembly meeting, to which Kooth was invited. The key question is "how" rather than "if" this problem should be addressed. We remain deeply humbled to be entrusted with the opportunity to be at the forefront of supporting a landmark programme in the most populous state in the US, in what we believe will be a template for future governments and health care systems on how to safeguard the mental health of the next generation.
I have been very proud to see how our whole team has stepped up to the opportunity in California, with both the work undertaken to win the contract in March and then subsequently the shift into the delivery phase. This is hard but purposeful work across 30 workstreams spanning the development of our next-generation platform, marketing and promotion strategy, as well as building our workforce and organisational infrastructure.
We are on track for the launch of our contract in California in January 2024, with all major milestones and deliverables to date met:
- All our US VP-level hires are in place to support go-live, with talent joining the existing team from organisations including Headspace, Crisis Text Line and Oracle Cerner. Hiring for other roles is broadly on track, with Kooth's fiscal rigour, transparency and growth as a public company adding appeal to candidates, in a market where many VC backed organisations are shedding staff to reduce cash burn.
- A beta version of Kooth's new mobile app is live in two counties in California as part of a 'soft launch' test. Over the next few months we will be adding, iterating, and gathering feedback from young people to help optimise the app and experience ahead of go-live in January.
Beyond California, our pilot project in Pennsylvania reached a significant milestone with almost 100,000 students having access to Kooth in the school year, with 1 in 10 high school students having used the platform, an uptake which surpassed our expectations based on our UK experience.
In the UK, following on from the reorganisation of NHS England from 135 Care Commissioning Groups into 42 Integrated Care Systems ("ICSs"), the headwinds in commissioning remain challenging, as ICSs adapt to a new funding environment. In 2023/24, ICSs must deliver 6% in real term efficiency savings, at a time when there is a 16% annual increase in demand for mental health support.
While Kooth is an advocate for digital transformation to address this challenge, we have seen Commissioners faced with tough short-term decisions to divert funds into acute care and reduce investments elsewhere. This is a challenge being experienced across the industry and is not unique to Kooth. While we have seen an increase in contracts that expand upon renewal to 52% (2022: 32%), gains were offset by £2.4m of churn, a combination of funding unavailable to continue pilot contracts, reductions as contracts consolidated and increased competition. Overall net revenue retention was 100% (2022: 107%).
In response to the current commissioning environment, we have used our market leading position to take action and better position ourselves for the future:
- We have restructured our commercial team with a focus on adding seniority and stakeholder management to engage NHS commissioners and Integrated Care Boards ("ICBs").
- We have grown and invested further in both our commissioner-marketing and user-marketing teams.
- We have launched an Integrated Digital Pathway ("IDP") service to help reduce pressure on CAMHS and IAPT services by providing support to individuals while on a waiting list, with the goal of discharging individuals if appropriate, or preventing further deterioration while awaiting treatment. We are currently piloting this unique service in two regions.
Management believes that these actions will help Kooth respond to the long-term opportunity that remains in helping ICSs to deliver on their vision to transform healthcare services, focus on prevention, and support the population health of their regions.
Kooth Adult (UK)
As a result of the pressures described above, our Kooth Adult services have been impacted more so than our service for children and young people, with ARR standing at £2.6m (FY2022: £3.0m). This is primarily due to newer contracts not being continued after a first year of piloting, as local commissioners seek to make budget available for acute service delivery.
Kooth Children and Young People (UK)
In contrast to the challenging commissioning environment in England, Kooth continues to expand in Scotland with new commissions in East Ayrshire, Inverclyde and North Lanarkshire.
From a product/service perspective, we anticipate strong interest from both children and young people, and commissioners in learning how our enhanced platform could better serve their needs. When California is live we intend to use this showcase to better demonstrate the step change that is possible through digital transformation in delivering a population-wide mental health strategy.
Current trading and outlook
Kooth will continue to invest significantly in its technology platform, systems and talent to deliver on our next generation platform for California. We will then bring these innovations to all US and UK customers to deliver enhanced support for all.
We continue to see both US State governments and Medicaid payers recognise the need to invest further in youth mental health and are optimistic about the significant opportunity that Kooth has in the US. For the UK, we expect the current situation to remain for some time, with our focus being on continuing to demonstrate the impact and savings that result when Kooth is commissioned in a region.
The Group remains confident of delivering revenue for the full year in line with our revised market guidance of no less than £34 million.
Our robust balance sheet enables us to invest to meet long-term, increasing demand for Kooth's services. We will continue this investment in our talent and technology to enable us to scale up to tackle what is one of the world's biggest challenges.
Tim Barker
Chief Executive
Chief Financial Officer's review
Kooth delivered a strong performance in the period supported by an increase across revenue and annual recurring revenue, a good gross margin as well as continuing to invest in our platform and the business for the half year ended 30 June 2023 as compared to the six months ended 30 June 2022.
Key Performance Indicators
Total Revenue
£11.7m | £9.0m | £8.0m | £5.9m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
As we continue to invest in and grow our business, revenue growth demonstrates the progress we are making.
Annual Recurring Revenue
£21.4m | £18.5m | £16.6m | £13.1m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Annual Recurring Revenue ("ARR") is the annualised revenue of customers engaged or closed as at the period end and is an indication of the upcoming annual value of the recurring revenue. This is used by management to monitor the long term revenue growth of the business.
Gross Margin
66.8% | 68.4% | 69.4% | 69.6% |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Gross Profit as a percentage of revenue. Direct costs are the costs of our practitioners directly involved in the delivery of our services.
Adjusted EBITDA
£0.0m | £0.5m | £1.1m | £0.5m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Earnings before interest, tax, depreciation and amortisation in the period, adjusted for share based payments and exceptional costs. This metric provides a more comparable indication of the Group's core business performance by removing the impact of non-trading items that are reported separately.
Number of customers
149 | 141 | 142 | 104 |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
The total number of live contracts with customers. As the NHS finalised the consolidation from 135 Clinical Commissioning Groups to 42 Integrated Care Systems in the last year, we are seeing a shift to fewer, larger contracts spanning the whole population within an ICS region.
Service user logins
1.4m | 1.4m | 1.2m | 1.0m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
The number of logins to Kooth from users, demonstrating uptake of our service.
Revenue
Revenue increased by 29% to £11.7m (2022 H1: £9.0m), Annual Recurring Revenue grew by 16% to £21.4m (2022 H1: £18.5m), with ten new contracts won in the first half of 2023. The revenue increase is predominantly attributable to US revenue of £1.8m in H1 2023 (2022 H1: £Nil) where we now have three contracts and included non-recurring revenue from the state of California for one-off research and pilot study work. This led to a slight decrease in recurring revenue (which comprises income invoiced for services that are repeatable, consumed and delivered on a monthly basis over the term of a customer contract) as a percentage of overall revenue from 95% to 94%.
Churn was 13% giving net revenue retention (measured by the total value of on-going ARR at the period-end from clients in place 12 months earlier as a percentage of the opening ARR from those clients) for the period to 30 June 2023 of 100%. This has decreased from 107% recorded in H1 2022 which is a result of an increase in churn within our English contracts where we are seeing the impact of funding being redirected to more acute care, a resizing of pilot adult contracts and a slowdown in uplifts as well as budgetary pressures as the NHS transitioned from a CCG to ICS structure.
Gross Profit
Gross Profit increased 26% from £6.2m to £7.8m with gross margin slightly down at 66.8% (2022 H1: 68.4%). Direct costs are the costs of the practitioners directly involved in the delivery of our services, a total of 251 at the period-end (2022 H1: 213 heads). Gross margin dropped in the UK as salary increases at the start of 2023 reflected inflationary pressures and we took a decision to enhance contract performance for the protection of longer-term growth. These were partially offset by the end of the 1.25% Health and Social Care Levy and a positive mix impact as our new US contracts ramped up.
Adjusted EBITDA
Adjusted EBITDA in the period decreased from £0.5m to £0.01m with an increased gross profit offset by a 38% increase in administrative expenses (excluding amortisation, depreciation and share based payments). Whilst UK costs increased in line with salary inflation and revenue growth requiring increased promotion spend, the majority of the increase related to the build out of the US teams supporting our Pennsylvania and California contracts.
The total charge for share based payments in the period was £0.4m (2022 H1: £0.02m). The increase reflects the annual issue of three year grants to all staff and a credit in 2022 following a reassessment of those grants subject to performance criteria. Depreciation and amortisation increased to £1.5m (2022 H1 £1.1m) as capital expenditure commenced on the US platform build.
Taxation
The overall tax credit for the six months ended 30 June 2023 (£1.2m) and 2022 (£0.2m) relate to Research and Development expenditure credits in addition to the movement in the deferred tax asset with the increase reflecting greater R&D spend and an increase in the effective tax rate on losses.
Loss after tax
The Group loss after tax for the period was £0.5m (2022 H1: £0.3m).
Balance Sheet
The strength of the Group's balance sheet with net assets of £10.6m (30 June 2022: £10.6m), plus a successful gross fundraise of £10m post half year end, and high levels of recurring revenue provide the Group with financial strength to execute on its investment strategy which continues to focus on US business development and platform investment.
Cash flow and financing
Cash outflow during the six months was £2.6m (2022 H1: £1.2m inflow). The focus on US platform investment gave rise to capital expenditure of £3.5m (2022 H1: £1.3m), offset by cash inflows from operating activities of £0.8m including receipt of an R&D government tax credit of £0.6m giving a net cash position at 30 June 2023 of £5.9m (2022 H1: £8.3m).
The Group remains debt free.
Forward-looking statements
Certain statements in this half year report are forward looking. Although the Group believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. Because these statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements.
Dividends
The Group's intention in the short to medium term is to invest in order to deliver capital growth for shareholders. The Board has not recommended an interim dividend payment in respect of the six months ended 30 June 2023 (2022: £nil) and does not anticipate recommending a dividend within the next year but may do so in future years.
Sanjay Jawa
Chief Financial Officer
Condensed Consolidated Statement of Comprehensive Income
For the six months ended 30 June 2023
Note | Six months ended 30 June 2023 Unaudited | Six months ended 30 June 2022 Unaudited | Year ended 31 December 2022 Audited | |
£'000 | £'000 | £'000 | ||
Revenue | 8 | 11,660 | 9,022 | 20,120 |
Cost of sales | (3,872) | (2,852) | (6,265) | |
Gross profit | 7,788 | 6,170 | 13,855 | |
Administrative expenses | (9,606) | (6,758) | (14,767) | |
Operating loss | (1,818) | (588) | (912) | |
Analysed as: | ||||
Adjusted EBITDA | 9 | 539 | 1,612 | |
Depreciation & amortisation | 11 | (1,451) | (1,109) | (2,232) |
Share based payment expense | (376) | (18) | (292) | |
Operating loss | (1,818) | (588) | (912) | |
Interest income | 91 | 17 | 81 | |
Loss before tax | (1,727) | (571) | (831) | |
Tax | 9 | 1,202 | 229 | 115 |
Total comprehensive loss for the period | (525) | (342) | (716) | |
Loss per share - basic (£) | 10 | (0.02) | (0.01) | (0.02) |
Loss per share - diluted (£) | 10 | (0.02) | (0.01) | (0.02)
|
Condensed Consolidated Balance Sheet
As at 30 June 2023
Note | 30 June 2023 Unaudited | 30 June 2022 Unaudited | 31 December 2022 Audited | |
£'000 | £'000 | £'000 | ||
Assets | ||||
Non-current assets | ||||
Goodwill | 511 | 511 | 511 | |
Development costs | 11 | 5,794 | 3,075 | 3,681 |
Right of use asset | 53 | - | 68 | |
Property, plant and equipment | 150 | 96 | 122 | |
Deferred tax asset | 1,626 | 420 | - | |
Total non-current assets | 8,134 | 4,102 | 4,382 | |
Current assets | ||||
Trade and other receivables | 12 | 2,355 | 2,632 | 2,618 |
Contract assets | 180 | 426 | 649 | |
Cash and cash equivalents | 5,850 | 8,310 | 8,492 | |
Total current assets | 8,385 | 11,368 | 11,759 | |
Total assets | 16,519 | 15,470 | 16,141 | |
Liabilities | ||||
Current liabilities | ||||
Trade payables | (1,047) | (331) | (680) | |
Contract liabilities | (3,096) | (2,797) | (2,583) | |
Lease liability | (54) | - | (68) | |
Accruals and other creditors | (913) | (737) | (977) | |
Deferred tax liabilities | - | - | (348) | |
Tax liabilities | (769) | (956) | (967) | |
Total current liabilities | (5,879) | (4,821) | (5,623) | |
Net current assets | 2,506 | 6,547 | 6,136 | |
Net assets | 10,640 | 10,649 | 10,518 | |
Equity | ||||
Share capital | 1,653 | 1,653 | 1,653 | |
Share premium account | 14,229 | 14,229 | 14,229 | |
Retained earnings | (3,120) | (2,221) | (2,595) | |
Share-based payment reserve | 1,867 | 977 | 1,221 | |
Capital redemption reserve | 115 | 115 | 115 | |
Merger reserve | (4,104) | (4,104) | (4,104) | |
Total equity | 10,640 | 10,649 | 10,518 |
Condensed Consolidated Statement of Cash Flows
For the six months ended 30 June 2023
Six months ended 30 June 2023 Unaudited | Six months ended 30 June 2022 Unaudited | Year ended 31 December 2022 Audited | ||
£'000 | £'000 | £'000 | ||
Cash flows from operating activities | ||||
Loss for the period | (525) | (342) | (716) | |
Adjusted for: | ||||
Depreciation & amortisation | 1,451 | 1,109 | 2,232 | |
Income tax received | 569 | 330 | 330 | |
Share based payment expense | 376 | 18 | 292 | |
Tax income recognised | (1,202) | (229) | (115) | |
Interest income | (91) | - | (81) | |
Movements in working capital: | ||||
(Increase) / decrease in trade and other receivables | 651 | (369) | 78 | |
Increase / (decrease) in trade and other payables | (384) | 2,009 | 2,364 | |
Net cashflow from operating activities | 845 | 2,527 | 4,384 | |
Cash flows from investing activities | ||||
Purchase of property, plant and equipment | (70) | (28) | (100) | |
Additions to intangible assets | (3,508) | (1,268) | (2,952) | |
Net cash used in investing activities | (3,578) | (1,296) | (3,052) | |
Cash flows from financing activities | ||||
Interest income | 91 | - | 81 | |
Net cash from financing activities | 91 | - | 81 | |
Net increase / (decrease) in cash and cash equivalents | (2,642) | 1,231 | 1,413 | |
Cash and cash equivalents at the beginning of the period | 8,492 | 7,079 | 7,079 | |
Cash and cash equivalents at the end of the period | 5,850 | 8,310 | 8,492 |
Condensed Consolidated Statement of Changes in Equity
For the six months ended 30 June 2023
Share Capital | Share Premium | Share Based Payment Reserve | Retained Eearnings | Capital Redemption Reserve | Merger reserve | Total Equity | |
Balance at 1 January 2022 | 1,653 | 14,229 | 959 | (1,879) | 115 | (4,104) | 10,973 |
Share based payments | - | - | 18 | - | - | - | 18 |
Total comprehensive income for the period | - | - | - | (342) | - | - | (342) |
As at 30 June 2022 | 1,653 | 14,229 | 977 | (2,221) | 115 | (4,104) | 10,649 |
Balance at 1 July 2022 | 1,653 | 14,229 | 977 | (2,221) | 115 | (4,104) | 10,649 |
Share based payments | - | - | 244 | - | - | - | 244 |
Total comprehensive income for the period | - | - | - | (374) | - | - | (374) |
As at 31 December 2022 | 1,653 | 14,229 | 1,221 | (2,595) | 115 | (4,104) | 10,519 |
Balance at 1 January 2023 | 1,653 | 14,229 | 1,221 | (2,595) | 115 | (4,104) | 10,519 |
Share based payments | - | - | 646 | - | - | - | 646 |
Total comprehensive income for the period | - | - | - | (525) | - | - | (525) |
As at 30 June 2023 | 1,653 | 14,229 | 1,867 | (3,120) | 115 | (4,104) | 10,640 |
2023
Half-year Results
21 September 2023
Strategic momentum and revenue growth of 29%
Full year revenue guidance of at least £34m
Kooth (AIM: KOO), a global leader in youth digital mental well-being, announces unaudited half year results for the six months ended 30 June 2023. All figures relate to this period unless otherwise stated.
Strategic and post period end highlights
- Transformational US contract win in California, $188m minimum value
- On track for California go-live in January 2024, notably with the Kooth mobile app and hires
- Number one provider of mental health access for children and young people to NHS England
- Significant uptake of Kooth in Pennsylvania pilot, providing access to c.100,000 school students
- Ongoing investment in business development, platform investment and US expansion
Financial Highlights
- Revenues up 29% to £11.7m (2022: £9.0m)
- Annual Recurring Revenue (ARR) up 16% to £21.4m (2022: £18.5m)
- Gross margin of 66.8% (2022: 68.4%)
- Adjusted EBITDA of £0.01m (2022: £0.5m) reflecting investment in US setup and business development
- Recurring Revenue from contracts 12 months or longer 94% (2022: 95%)
- Robust balance sheet; net cash of £5.9m plus successful gross fundraise of £10m post half-year end supports investment for long-term growth
Outlook
- Significant opportunity for Kooth in the US driven by the continued need from both US State governments and Medicaid payers to invest further in youth mental health
- For the UK, we expect the headwinds to remain, reflecting a focus on NHS cost saving and acute care backlog. Our focus remains on continuing to demonstrate the impact and savings that Kooth generates when commissioned in a region
- The Group remains confident of delivering revenue for the full year in line with our revised market guidance of no less than £34 million
- Our robust balance sheet enables us to invest to meet long-term, increasing demand for Kooth's services
Tim Barker, Chief Executive Officer of Kooth, said:
The first six months of 2023 have been a period of significant, and positive, change for Kooth. In March we announced our largest contract to date with the State of California which was finalised, post-period end, as a four year, $188m minimum value agreement. This marked Kooth's second major engagement in the US, alongside Pennsylvania, which was agreed in October 2022. During the period, and over the last 12 months, we have developed a significant operation in the United States as we look to capture the opportunity this major healthcare market brings. We look forward to leveraging our platform to increase the size of our business further and, more importantly, help improve mental health provision to as many young people as possible.
In the UK, we are not immune to the broader healthcare and economic environment, which sees commissioning across the NHS structure under stress as Integrated Care Systems prioritise a reduction in costs and tackling an acute mental healthcare backlog. In response, we have taken proactive steps to position ourselves to best respond to this environment, including developing new services to help tackle waiting lists.
I would like to thank our team for their work which has delivered transformational gains during the period and beyond as we look to leverage our position as a pioneer and innovator in digital mental healthcare to deliver the care needed to help tackle the growing crisis in global mental health.
Financial headlines
Six months ended 30 June 2023 | Six months ended 30 June 2022 | Change | |||
£'000 | £'000 | ||||
Revenue | |||||
Total revenue | 11,660 | 9,022 | +29.2% | ||
Annual Recurring Revenue | 21,376 | 18,483 | +15.7% | ||
Gross profit | 7,788 | 6,170 | +26.2% | ||
Gross margin | 66.8% | 68.4% | -2.3ppt | ||
Adjusted EBITDA | 9 | 539 | -98.3% | ||
Profit/(Loss) after tax for the period | (525) | (342) | -53.5% | ||
Cash generation | (2,642) | 1,231 | -314.6% | ||
Cash position | 5,850 | 8,310 | -29.6% | ||
Earnings per share (£) | (0.02) | (0.01) | -58.8% |
Enquiries Kooth plc | |
Tim Barker, CEO | |
Panmure Gordon, Nominated Adviser and Joint Broker | +44 (0) 20 7886 2500 |
Stifel Nicolaus Europe Limited, Joint Broker | +44 (0) 20 7710 7600 |
FTI Consulting |
About Kooth
Kooth (AIM:KOO) is a global leader in youth digital mental well-being. Our mission is to provide accessible and safe spaces for everyone to achieve better mental health. Our platform is clinically robust and accredited to provide a range of therapeutic support and interventions. All our services are predicated on easy access to make early intervention and prevention a reality.
Our three services are:
- Kooth: for children and young people
- Kooth: for adults
- Kooth Work: for frontline employees
Kooth is a fully safeguarded and pre-moderated community with a library of peer and professional created content, alongside access to experienced online counsellors. There are no thresholds for support and no waiting lists. Currently, Kooth sees more than 4,000 logins a day.
Kooth is the only digital mental health provider to hold a UK-wide accreditation from the British Association of Counselling and Psychotherapy (BACP) and according to NHS England data for 2021/22 is now the largest single access provider for mental health support for under 18s.
In 2021, Kooth began executing on its international expansion strategy, with an initial focus on the US market. This focus is due to the growing recognition of the importance of improving youth mental health in this key global healthcare market, with 1-in-6 people aged 6-17 experiencing a mental health disorder each year. Kooth's first major pilot contract in the US was signed in October 2022 with the State of Pennsylvania followed in July 2023 by a four-year contract to cover all six million 13-25 year-olds in the State of California.
Chief Executive's Review
Transformational strategic progress
With the award of a $188m four-year state-wide contract with California, the last six months demonstrate the significant opportunity for Kooth in the US as federal and state governments invest to transform youth mental health care.
As one of the work streams within the State of California's $4.7 billion youth masterplan, this investment arguably represents the world's most progressive initiative to improve youth mental health. This was evident at the September UN Congress General Assembly meeting, to which Kooth was invited. The key question is "how" rather than "if" this problem should be addressed. We remain deeply humbled to be entrusted with the opportunity to be at the forefront of supporting a landmark programme in the most populous state in the US, in what we believe will be a template for future governments and health care systems on how to safeguard the mental health of the next generation.
I have been very proud to see how our whole team has stepped up to the opportunity in California, with both the work undertaken to win the contract in March and then subsequently the shift into the delivery phase. This is hard but purposeful work across 30 workstreams spanning the development of our next-generation platform, marketing and promotion strategy, as well as building our workforce and organisational infrastructure.
We are on track for the launch of our contract in California in January 2024, with all major milestones and deliverables to date met:
- All our US VP-level hires are in place to support go-live, with talent joining the existing team from organisations including Headspace, Crisis Text Line and Oracle Cerner. Hiring for other roles is broadly on track, with Kooth's fiscal rigour, transparency and growth as a public company adding appeal to candidates, in a market where many VC backed organisations are shedding staff to reduce cash burn.
- A beta version of Kooth's new mobile app is live in two counties in California as part of a 'soft launch' test. Over the next few months we will be adding, iterating, and gathering feedback from young people to help optimise the app and experience ahead of go-live in January.
Beyond California, our pilot project in Pennsylvania reached a significant milestone with almost 100,000 students having access to Kooth in the school year, with 1 in 10 high school students having used the platform, an uptake which surpassed our expectations based on our UK experience.
In the UK, following on from the reorganisation of NHS England from 135 Care Commissioning Groups into 42 Integrated Care Systems ("ICSs"), the headwinds in commissioning remain challenging, as ICSs adapt to a new funding environment. In 2023/24, ICSs must deliver 6% in real term efficiency savings, at a time when there is a 16% annual increase in demand for mental health support.
While Kooth is an advocate for digital transformation to address this challenge, we have seen Commissioners faced with tough short-term decisions to divert funds into acute care and reduce investments elsewhere. This is a challenge being experienced across the industry and is not unique to Kooth. While we have seen an increase in contracts that expand upon renewal to 52% (2022: 32%), gains were offset by £2.4m of churn, a combination of funding unavailable to continue pilot contracts, reductions as contracts consolidated and increased competition. Overall net revenue retention was 100% (2022: 107%).
In response to the current commissioning environment, we have used our market leading position to take action and better position ourselves for the future:
- We have restructured our commercial team with a focus on adding seniority and stakeholder management to engage NHS commissioners and Integrated Care Boards ("ICBs").
- We have grown and invested further in both our commissioner-marketing and user-marketing teams.
- We have launched an Integrated Digital Pathway ("IDP") service to help reduce pressure on CAMHS and IAPT services by providing support to individuals while on a waiting list, with the goal of discharging individuals if appropriate, or preventing further deterioration while awaiting treatment. We are currently piloting this unique service in two regions.
Management believes that these actions will help Kooth respond to the long-term opportunity that remains in helping ICSs to deliver on their vision to transform healthcare services, focus on prevention, and support the population health of their regions.
Kooth Adult (UK)
As a result of the pressures described above, our Kooth Adult services have been impacted more so than our service for children and young people, with ARR standing at £2.6m (FY2022: £3.0m). This is primarily due to newer contracts not being continued after a first year of piloting, as local commissioners seek to make budget available for acute service delivery.
Kooth Children and Young People (UK)
In contrast to the challenging commissioning environment in England, Kooth continues to expand in Scotland with new commissions in East Ayrshire, Inverclyde and North Lanarkshire.
From a product/service perspective, we anticipate strong interest from both children and young people, and commissioners in learning how our enhanced platform could better serve their needs. When California is live we intend to use this showcase to better demonstrate the step change that is possible through digital transformation in delivering a population-wide mental health strategy.
Current trading and outlook
Kooth will continue to invest significantly in its technology platform, systems and talent to deliver on our next generation platform for California. We will then bring these innovations to all US and UK customers to deliver enhanced support for all.
We continue to see both US State governments and Medicaid payers recognise the need to invest further in youth mental health and are optimistic about the significant opportunity that Kooth has in the US. For the UK, we expect the current situation to remain for some time, with our focus being on continuing to demonstrate the impact and savings that result when Kooth is commissioned in a region.
The Group remains confident of delivering revenue for the full year in line with our revised market guidance of no less than £34 million.
Our robust balance sheet enables us to invest to meet long-term, increasing demand for Kooth's services. We will continue this investment in our talent and technology to enable us to scale up to tackle what is one of the world's biggest challenges.
Tim Barker
Chief Executive
Chief Financial Officer's review
Kooth delivered a strong performance in the period supported by an increase across revenue and annual recurring revenue, a good gross margin as well as continuing to invest in our platform and the business for the half year ended 30 June 2023 as compared to the six months ended 30 June 2022.
Key Performance Indicators
Total Revenue
£11.7m | £9.0m | £8.0m | £5.9m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
As we continue to invest in and grow our business, revenue growth demonstrates the progress we are making.
Annual Recurring Revenue
£21.4m | £18.5m | £16.6m | £13.1m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Annual Recurring Revenue ("ARR") is the annualised revenue of customers engaged or closed as at the period end and is an indication of the upcoming annual value of the recurring revenue. This is used by management to monitor the long term revenue growth of the business.
Gross Margin
66.8% | 68.4% | 69.4% | 69.6% |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Gross Profit as a percentage of revenue. Direct costs are the costs of our practitioners directly involved in the delivery of our services.
Adjusted EBITDA
£0.0m | £0.5m | £1.1m | £0.5m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Earnings before interest, tax, depreciation and amortisation in the period, adjusted for share based payments and exceptional costs. This metric provides a more comparable indication of the Group's core business performance by removing the impact of non-trading items that are reported separately.
Number of customers
149 | 141 | 142 | 104 |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
The total number of live contracts with customers. As the NHS finalised the consolidation from 135 Clinical Commissioning Groups to 42 Integrated Care Systems in the last year, we are seeing a shift to fewer, larger contracts spanning the whole population within an ICS region.
Service user logins
1.4m | 1.4m | 1.2m | 1.0m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
The number of logins to Kooth from users, demonstrating uptake of our service.
Revenue
Revenue increased by 29% to £11.7m (2022 H1: £9.0m), Annual Recurring Revenue grew by 16% to £21.4m (2022 H1: £18.5m), with ten new contracts won in the first half of 2023. The revenue increase is predominantly attributable to US revenue of £1.8m in H1 2023 (2022 H1: £Nil) where we now have three contracts and included non-recurring revenue from the state of California for one-off research and pilot study work. This led to a slight decrease in recurring revenue (which comprises income invoiced for services that are repeatable, consumed and delivered on a monthly basis over the term of a customer contract) as a percentage of overall revenue from 95% to 94%.
Churn was 13% giving net revenue retention (measured by the total value of on-going ARR at the period-end from clients in place 12 months earlier as a percentage of the opening ARR from those clients) for the period to 30 June 2023 of 100%. This has decreased from 107% recorded in H1 2022 which is a result of an increase in churn within our English contracts where we are seeing the impact of funding being redirected to more acute care, a resizing of pilot adult contracts and a slowdown in uplifts as well as budgetary pressures as the NHS transitioned from a CCG to ICS structure.
Gross Profit
Gross Profit increased 26% from £6.2m to £7.8m with gross margin slightly down at 66.8% (2022 H1: 68.4%). Direct costs are the costs of the practitioners directly involved in the delivery of our services, a total of 251 at the period-end (2022 H1: 213 heads). Gross margin dropped in the UK as salary increases at the start of 2023 reflected inflationary pressures and we took a decision to enhance contract performance for the protection of longer-term growth. These were partially offset by the end of the 1.25% Health and Social Care Levy and a positive mix impact as our new US contracts ramped up.
Adjusted EBITDA
Adjusted EBITDA in the period decreased from £0.5m to £0.01m with an increased gross profit offset by a 38% increase in administrative expenses (excluding amortisation, depreciation and share based payments). Whilst UK costs increased in line with salary inflation and revenue growth requiring increased promotion spend, the majority of the increase related to the build out of the US teams supporting our Pennsylvania and California contracts.
The total charge for share based payments in the period was £0.4m (2022 H1: £0.02m). The increase reflects the annual issue of three year grants to all staff and a credit in 2022 following a reassessment of those grants subject to performance criteria. Depreciation and amortisation increased to £1.5m (2022 H1 £1.1m) as capital expenditure commenced on the US platform build.
Taxation
The overall tax credit for the six months ended 30 June 2023 (£1.2m) and 2022 (£0.2m) relate to Research and Development expenditure credits in addition to the movement in the deferred tax asset with the increase reflecting greater R&D spend and an increase in the effective tax rate on losses.
Loss after tax
The Group loss after tax for the period was £0.5m (2022 H1: £0.3m).
Balance Sheet
The strength of the Group's balance sheet with net assets of £10.6m (30 June 2022: £10.6m), plus a successful gross fundraise of £10m post half year end, and high levels of recurring revenue provide the Group with financial strength to execute on its investment strategy which continues to focus on US business development and platform investment.
Cash flow and financing
Cash outflow during the six months was £2.6m (2022 H1: £1.2m inflow). The focus on US platform investment gave rise to capital expenditure of £3.5m (2022 H1: £1.3m), offset by cash inflows from operating activities of £0.8m including receipt of an R&D government tax credit of £0.6m giving a net cash position at 30 June 2023 of £5.9m (2022 H1: £8.3m).
The Group remains debt free.
Forward-looking statements
Certain statements in this half year report are forward looking. Although the Group believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. Because these statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements.
Dividends
The Group's intention in the short to medium term is to invest in order to deliver capital growth for shareholders. The Board has not recommended an interim dividend payment in respect of the six months ended 30 June 2023 (2022: £nil) and does not anticipate recommending a dividend within the next year but may do so in future years.
Sanjay Jawa
Chief Financial Officer
Condensed Consolidated Statement of Comprehensive Income
For the six months ended 30 June 2023
Note | Six months ended 30 June 2023 Unaudited | Six months ended 30 June 2022 Unaudited | Year ended 31 December 2022 Audited | |
£'000 | £'000 | £'000 | ||
Revenue | 8 | 11,660 | 9,022 | 20,120 |
Cost of sales | (3,872) | (2,852) | (6,265) | |
Gross profit | 7,788 | 6,170 | 13,855 | |
Administrative expenses | (9,606) | (6,758) | (14,767) | |
Operating loss | (1,818) | (588) | (912) | |
Analysed as: | ||||
Adjusted EBITDA | 9 | 539 | 1,612 | |
Depreciation & amortisation | 11 | (1,451) | (1,109) | (2,232) |
Share based payment expense | (376) | (18) | (292) | |
Operating loss | (1,818) | (588) | (912) | |
Interest income | 91 | 17 | 81 | |
Loss before tax | (1,727) | (571) | (831) | |
Tax | 9 | 1,202 | 229 | 115 |
Total comprehensive loss for the period | (525) | (342) | (716) | |
Loss per share - basic (£) | 10 | (0.02) | (0.01) | (0.02) |
Loss per share - diluted (£) | 10 | (0.02) | (0.01) | (0.02)
|
Condensed Consolidated Balance Sheet
As at 30 June 2023
Note | 30 June 2023 Unaudited | 30 June 2022 Unaudited | 31 December 2022 Audited | |
£'000 | £'000 | £'000 | ||
Assets | ||||
Non-current assets | ||||
Goodwill | 511 | 511 | 511 | |
Development costs | 11 | 5,794 | 3,075 | 3,681 |
Right of use asset | 53 | - | 68 | |
Property, plant and equipment | 150 | 96 | 122 | |
Deferred tax asset | 1,626 | 420 | - | |
Total non-current assets | 8,134 | 4,102 | 4,382 | |
Current assets | ||||
Trade and other receivables | 12 | 2,355 | 2,632 | 2,618 |
Contract assets | 180 | 426 | 649 | |
Cash and cash equivalents | 5,850 | 8,310 | 8,492 | |
Total current assets | 8,385 | 11,368 | 11,759 | |
Total assets | 16,519 | 15,470 | 16,141 | |
Liabilities | ||||
Current liabilities | ||||
Trade payables | (1,047) | (331) | (680) | |
Contract liabilities | (3,096) | (2,797) | (2,583) | |
Lease liability | (54) | - | (68) | |
Accruals and other creditors | (913) | (737) | (977) | |
Deferred tax liabilities | - | - | (348) | |
Tax liabilities | (769) | (956) | (967) | |
Total current liabilities | (5,879) | (4,821) | (5,623) | |
Net current assets | 2,506 | 6,547 | 6,136 | |
Net assets | 10,640 | 10,649 | 10,518 | |
Equity | ||||
Share capital | 1,653 | 1,653 | 1,653 | |
Share premium account | 14,229 | 14,229 | 14,229 | |
Retained earnings | (3,120) | (2,221) | (2,595) | |
Share-based payment reserve | 1,867 | 977 | 1,221 | |
Capital redemption reserve | 115 | 115 | 115 | |
Merger reserve | (4,104) | (4,104) | (4,104) | |
Total equity | 10,640 | 10,649 | 10,518 |
Condensed Consolidated Statement of Cash Flows
For the six months ended 30 June 2023
Six months ended 30 June 2023 Unaudited | Six months ended 30 June 2022 Unaudited | Year ended 31 December 2022 Audited | ||
£'000 | £'000 | £'000 | ||
Cash flows from operating activities | ||||
Loss for the period | (525) | (342) | (716) | |
Adjusted for: | ||||
Depreciation & amortisation | 1,451 | 1,109 | 2,232 | |
Income tax received | 569 | 330 | 330 | |
Share based payment expense | 376 | 18 | 292 | |
Tax income recognised | (1,202) | (229) | (115) | |
Interest income | (91) | - | (81) | |
Movements in working capital: | ||||
(Increase) / decrease in trade and other receivables | 651 | (369) | 78 | |
Increase / (decrease) in trade and other payables | (384) | 2,009 | 2,364 | |
Net cashflow from operating activities | 845 | 2,527 | 4,384 | |
Cash flows from investing activities | ||||
Purchase of property, plant and equipment | (70) | (28) | (100) | |
Additions to intangible assets | (3,508) | (1,268) | (2,952) | |
Net cash used in investing activities | (3,578) | (1,296) | (3,052) | |
Cash flows from financing activities | ||||
Interest income | 91 | - | 81 | |
Net cash from financing activities | 91 | - | 81 | |
Net increase / (decrease) in cash and cash equivalents | (2,642) | 1,231 | 1,413 | |
Cash and cash equivalents at the beginning of the period | 8,492 | 7,079 | 7,079 | |
Cash and cash equivalents at the end of the period | 5,850 | 8,310 | 8,492 |
Condensed Consolidated Statement of Changes in Equity
For the six months ended 30 June 2023
Share Capital | Share Premium | Share Based Payment Reserve | Retained Eearnings | Capital Redemption Reserve | Merger reserve | Total Equity | |
Balance at 1 January 2022 | 1,653 | 14,229 | 959 | (1,879) | 115 | (4,104) | 10,973 |
Share based payments | - | - | 18 | - | - | - | 18 |
Total comprehensive income for the period | - | - | - | (342) | - | - | (342) |
As at 30 June 2022 | 1,653 | 14,229 | 977 | (2,221) | 115 | (4,104) | 10,649 |
Balance at 1 July 2022 | 1,653 | 14,229 | 977 | (2,221) | 115 | (4,104) | 10,649 |
Share based payments | - | - | 244 | - | - | - | 244 |
Total comprehensive income for the period | - | - | - | (374) | - | - | (374) |
As at 31 December 2022 | 1,653 | 14,229 | 1,221 | (2,595) | 115 | (4,104) | 10,519 |
Balance at 1 January 2023 | 1,653 | 14,229 | 1,221 | (2,595) | 115 | (4,104) | 10,519 |
Share based payments | - | - | 646 | - | - | - | 646 |
Total comprehensive income for the period | - | - | - | (525) | - | - | (525) |
As at 30 June 2023 | 1,653 | 14,229 | 1,867 | (3,120) | 115 | (4,104) | 10,640 |
2022
Half-year Results
21 September 2023
Strategic momentum and revenue growth of 29%
Full year revenue guidance of at least £34m
Kooth (AIM: KOO), a global leader in youth digital mental well-being, announces unaudited half year results for the six months ended 30 June 2023. All figures relate to this period unless otherwise stated.
Strategic and post period end highlights
- Transformational US contract win in California, $188m minimum value
- On track for California go-live in January 2024, notably with the Kooth mobile app and hires
- Number one provider of mental health access for children and young people to NHS England
- Significant uptake of Kooth in Pennsylvania pilot, providing access to c.100,000 school students
- Ongoing investment in business development, platform investment and US expansion
Financial Highlights
- Revenues up 29% to £11.7m (2022: £9.0m)
- Annual Recurring Revenue (ARR) up 16% to £21.4m (2022: £18.5m)
- Gross margin of 66.8% (2022: 68.4%)
- Adjusted EBITDA of £0.01m (2022: £0.5m) reflecting investment in US setup and business development
- Recurring Revenue from contracts 12 months or longer 94% (2022: 95%)
- Robust balance sheet; net cash of £5.9m plus successful gross fundraise of £10m post half-year end supports investment for long-term growth
Outlook
- Significant opportunity for Kooth in the US driven by the continued need from both US State governments and Medicaid payers to invest further in youth mental health
- For the UK, we expect the headwinds to remain, reflecting a focus on NHS cost saving and acute care backlog. Our focus remains on continuing to demonstrate the impact and savings that Kooth generates when commissioned in a region
- The Group remains confident of delivering revenue for the full year in line with our revised market guidance of no less than £34 million
- Our robust balance sheet enables us to invest to meet long-term, increasing demand for Kooth's services
Tim Barker, Chief Executive Officer of Kooth, said:
The first six months of 2023 have been a period of significant, and positive, change for Kooth. In March we announced our largest contract to date with the State of California which was finalised, post-period end, as a four year, $188m minimum value agreement. This marked Kooth's second major engagement in the US, alongside Pennsylvania, which was agreed in October 2022. During the period, and over the last 12 months, we have developed a significant operation in the United States as we look to capture the opportunity this major healthcare market brings. We look forward to leveraging our platform to increase the size of our business further and, more importantly, help improve mental health provision to as many young people as possible.
In the UK, we are not immune to the broader healthcare and economic environment, which sees commissioning across the NHS structure under stress as Integrated Care Systems prioritise a reduction in costs and tackling an acute mental healthcare backlog. In response, we have taken proactive steps to position ourselves to best respond to this environment, including developing new services to help tackle waiting lists.
I would like to thank our team for their work which has delivered transformational gains during the period and beyond as we look to leverage our position as a pioneer and innovator in digital mental healthcare to deliver the care needed to help tackle the growing crisis in global mental health.
Financial headlines
Six months ended 30 June 2023 | Six months ended 30 June 2022 | Change | |||
£'000 | £'000 | ||||
Revenue | |||||
Total revenue | 11,660 | 9,022 | +29.2% | ||
Annual Recurring Revenue | 21,376 | 18,483 | +15.7% | ||
Gross profit | 7,788 | 6,170 | +26.2% | ||
Gross margin | 66.8% | 68.4% | -2.3ppt | ||
Adjusted EBITDA | 9 | 539 | -98.3% | ||
Profit/(Loss) after tax for the period | (525) | (342) | -53.5% | ||
Cash generation | (2,642) | 1,231 | -314.6% | ||
Cash position | 5,850 | 8,310 | -29.6% | ||
Earnings per share (£) | (0.02) | (0.01) | -58.8% |
Enquiries Kooth plc | |
Tim Barker, CEO | |
Panmure Gordon, Nominated Adviser and Joint Broker | +44 (0) 20 7886 2500 |
Stifel Nicolaus Europe Limited, Joint Broker | +44 (0) 20 7710 7600 |
FTI Consulting |
About Kooth
Kooth (AIM:KOO) is a global leader in youth digital mental well-being. Our mission is to provide accessible and safe spaces for everyone to achieve better mental health. Our platform is clinically robust and accredited to provide a range of therapeutic support and interventions. All our services are predicated on easy access to make early intervention and prevention a reality.
Our three services are:
- Kooth: for children and young people
- Kooth: for adults
- Kooth Work: for frontline employees
Kooth is a fully safeguarded and pre-moderated community with a library of peer and professional created content, alongside access to experienced online counsellors. There are no thresholds for support and no waiting lists. Currently, Kooth sees more than 4,000 logins a day.
Kooth is the only digital mental health provider to hold a UK-wide accreditation from the British Association of Counselling and Psychotherapy (BACP) and according to NHS England data for 2021/22 is now the largest single access provider for mental health support for under 18s.
In 2021, Kooth began executing on its international expansion strategy, with an initial focus on the US market. This focus is due to the growing recognition of the importance of improving youth mental health in this key global healthcare market, with 1-in-6 people aged 6-17 experiencing a mental health disorder each year. Kooth's first major pilot contract in the US was signed in October 2022 with the State of Pennsylvania followed in July 2023 by a four-year contract to cover all six million 13-25 year-olds in the State of California.
Chief Executive's Review
Transformational strategic progress
With the award of a $188m four-year state-wide contract with California, the last six months demonstrate the significant opportunity for Kooth in the US as federal and state governments invest to transform youth mental health care.
As one of the work streams within the State of California's $4.7 billion youth masterplan, this investment arguably represents the world's most progressive initiative to improve youth mental health. This was evident at the September UN Congress General Assembly meeting, to which Kooth was invited. The key question is "how" rather than "if" this problem should be addressed. We remain deeply humbled to be entrusted with the opportunity to be at the forefront of supporting a landmark programme in the most populous state in the US, in what we believe will be a template for future governments and health care systems on how to safeguard the mental health of the next generation.
I have been very proud to see how our whole team has stepped up to the opportunity in California, with both the work undertaken to win the contract in March and then subsequently the shift into the delivery phase. This is hard but purposeful work across 30 workstreams spanning the development of our next-generation platform, marketing and promotion strategy, as well as building our workforce and organisational infrastructure.
We are on track for the launch of our contract in California in January 2024, with all major milestones and deliverables to date met:
- All our US VP-level hires are in place to support go-live, with talent joining the existing team from organisations including Headspace, Crisis Text Line and Oracle Cerner. Hiring for other roles is broadly on track, with Kooth's fiscal rigour, transparency and growth as a public company adding appeal to candidates, in a market where many VC backed organisations are shedding staff to reduce cash burn.
- A beta version of Kooth's new mobile app is live in two counties in California as part of a 'soft launch' test. Over the next few months we will be adding, iterating, and gathering feedback from young people to help optimise the app and experience ahead of go-live in January.
Beyond California, our pilot project in Pennsylvania reached a significant milestone with almost 100,000 students having access to Kooth in the school year, with 1 in 10 high school students having used the platform, an uptake which surpassed our expectations based on our UK experience.
In the UK, following on from the reorganisation of NHS England from 135 Care Commissioning Groups into 42 Integrated Care Systems ("ICSs"), the headwinds in commissioning remain challenging, as ICSs adapt to a new funding environment. In 2023/24, ICSs must deliver 6% in real term efficiency savings, at a time when there is a 16% annual increase in demand for mental health support.
While Kooth is an advocate for digital transformation to address this challenge, we have seen Commissioners faced with tough short-term decisions to divert funds into acute care and reduce investments elsewhere. This is a challenge being experienced across the industry and is not unique to Kooth. While we have seen an increase in contracts that expand upon renewal to 52% (2022: 32%), gains were offset by £2.4m of churn, a combination of funding unavailable to continue pilot contracts, reductions as contracts consolidated and increased competition. Overall net revenue retention was 100% (2022: 107%).
In response to the current commissioning environment, we have used our market leading position to take action and better position ourselves for the future:
- We have restructured our commercial team with a focus on adding seniority and stakeholder management to engage NHS commissioners and Integrated Care Boards ("ICBs").
- We have grown and invested further in both our commissioner-marketing and user-marketing teams.
- We have launched an Integrated Digital Pathway ("IDP") service to help reduce pressure on CAMHS and IAPT services by providing support to individuals while on a waiting list, with the goal of discharging individuals if appropriate, or preventing further deterioration while awaiting treatment. We are currently piloting this unique service in two regions.
Management believes that these actions will help Kooth respond to the long-term opportunity that remains in helping ICSs to deliver on their vision to transform healthcare services, focus on prevention, and support the population health of their regions.
Kooth Adult (UK)
As a result of the pressures described above, our Kooth Adult services have been impacted more so than our service for children and young people, with ARR standing at £2.6m (FY2022: £3.0m). This is primarily due to newer contracts not being continued after a first year of piloting, as local commissioners seek to make budget available for acute service delivery.
Kooth Children and Young People (UK)
In contrast to the challenging commissioning environment in England, Kooth continues to expand in Scotland with new commissions in East Ayrshire, Inverclyde and North Lanarkshire.
From a product/service perspective, we anticipate strong interest from both children and young people, and commissioners in learning how our enhanced platform could better serve their needs. When California is live we intend to use this showcase to better demonstrate the step change that is possible through digital transformation in delivering a population-wide mental health strategy.
Current trading and outlook
Kooth will continue to invest significantly in its technology platform, systems and talent to deliver on our next generation platform for California. We will then bring these innovations to all US and UK customers to deliver enhanced support for all.
We continue to see both US State governments and Medicaid payers recognise the need to invest further in youth mental health and are optimistic about the significant opportunity that Kooth has in the US. For the UK, we expect the current situation to remain for some time, with our focus being on continuing to demonstrate the impact and savings that result when Kooth is commissioned in a region.
The Group remains confident of delivering revenue for the full year in line with our revised market guidance of no less than £34 million.
Our robust balance sheet enables us to invest to meet long-term, increasing demand for Kooth's services. We will continue this investment in our talent and technology to enable us to scale up to tackle what is one of the world's biggest challenges.
Tim Barker
Chief Executive
Chief Financial Officer's review
Kooth delivered a strong performance in the period supported by an increase across revenue and annual recurring revenue, a good gross margin as well as continuing to invest in our platform and the business for the half year ended 30 June 2023 as compared to the six months ended 30 June 2022.
Key Performance Indicators
Total Revenue
£11.7m | £9.0m | £8.0m | £5.9m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
As we continue to invest in and grow our business, revenue growth demonstrates the progress we are making.
Annual Recurring Revenue
£21.4m | £18.5m | £16.6m | £13.1m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Annual Recurring Revenue ("ARR") is the annualised revenue of customers engaged or closed as at the period end and is an indication of the upcoming annual value of the recurring revenue. This is used by management to monitor the long term revenue growth of the business.
Gross Margin
66.8% | 68.4% | 69.4% | 69.6% |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Gross Profit as a percentage of revenue. Direct costs are the costs of our practitioners directly involved in the delivery of our services.
Adjusted EBITDA
£0.0m | £0.5m | £1.1m | £0.5m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Earnings before interest, tax, depreciation and amortisation in the period, adjusted for share based payments and exceptional costs. This metric provides a more comparable indication of the Group's core business performance by removing the impact of non-trading items that are reported separately.
Number of customers
149 | 141 | 142 | 104 |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
The total number of live contracts with customers. As the NHS finalised the consolidation from 135 Clinical Commissioning Groups to 42 Integrated Care Systems in the last year, we are seeing a shift to fewer, larger contracts spanning the whole population within an ICS region.
Service user logins
1.4m | 1.4m | 1.2m | 1.0m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
The number of logins to Kooth from users, demonstrating uptake of our service.
Revenue
Revenue increased by 29% to £11.7m (2022 H1: £9.0m), Annual Recurring Revenue grew by 16% to £21.4m (2022 H1: £18.5m), with ten new contracts won in the first half of 2023. The revenue increase is predominantly attributable to US revenue of £1.8m in H1 2023 (2022 H1: £Nil) where we now have three contracts and included non-recurring revenue from the state of California for one-off research and pilot study work. This led to a slight decrease in recurring revenue (which comprises income invoiced for services that are repeatable, consumed and delivered on a monthly basis over the term of a customer contract) as a percentage of overall revenue from 95% to 94%.
Churn was 13% giving net revenue retention (measured by the total value of on-going ARR at the period-end from clients in place 12 months earlier as a percentage of the opening ARR from those clients) for the period to 30 June 2023 of 100%. This has decreased from 107% recorded in H1 2022 which is a result of an increase in churn within our English contracts where we are seeing the impact of funding being redirected to more acute care, a resizing of pilot adult contracts and a slowdown in uplifts as well as budgetary pressures as the NHS transitioned from a CCG to ICS structure.
Gross Profit
Gross Profit increased 26% from £6.2m to £7.8m with gross margin slightly down at 66.8% (2022 H1: 68.4%). Direct costs are the costs of the practitioners directly involved in the delivery of our services, a total of 251 at the period-end (2022 H1: 213 heads). Gross margin dropped in the UK as salary increases at the start of 2023 reflected inflationary pressures and we took a decision to enhance contract performance for the protection of longer-term growth. These were partially offset by the end of the 1.25% Health and Social Care Levy and a positive mix impact as our new US contracts ramped up.
Adjusted EBITDA
Adjusted EBITDA in the period decreased from £0.5m to £0.01m with an increased gross profit offset by a 38% increase in administrative expenses (excluding amortisation, depreciation and share based payments). Whilst UK costs increased in line with salary inflation and revenue growth requiring increased promotion spend, the majority of the increase related to the build out of the US teams supporting our Pennsylvania and California contracts.
The total charge for share based payments in the period was £0.4m (2022 H1: £0.02m). The increase reflects the annual issue of three year grants to all staff and a credit in 2022 following a reassessment of those grants subject to performance criteria. Depreciation and amortisation increased to £1.5m (2022 H1 £1.1m) as capital expenditure commenced on the US platform build.
Taxation
The overall tax credit for the six months ended 30 June 2023 (£1.2m) and 2022 (£0.2m) relate to Research and Development expenditure credits in addition to the movement in the deferred tax asset with the increase reflecting greater R&D spend and an increase in the effective tax rate on losses.
Loss after tax
The Group loss after tax for the period was £0.5m (2022 H1: £0.3m).
Balance Sheet
The strength of the Group's balance sheet with net assets of £10.6m (30 June 2022: £10.6m), plus a successful gross fundraise of £10m post half year end, and high levels of recurring revenue provide the Group with financial strength to execute on its investment strategy which continues to focus on US business development and platform investment.
Cash flow and financing
Cash outflow during the six months was £2.6m (2022 H1: £1.2m inflow). The focus on US platform investment gave rise to capital expenditure of £3.5m (2022 H1: £1.3m), offset by cash inflows from operating activities of £0.8m including receipt of an R&D government tax credit of £0.6m giving a net cash position at 30 June 2023 of £5.9m (2022 H1: £8.3m).
The Group remains debt free.
Forward-looking statements
Certain statements in this half year report are forward looking. Although the Group believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. Because these statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements.
Dividends
The Group's intention in the short to medium term is to invest in order to deliver capital growth for shareholders. The Board has not recommended an interim dividend payment in respect of the six months ended 30 June 2023 (2022: £nil) and does not anticipate recommending a dividend within the next year but may do so in future years.
Sanjay Jawa
Chief Financial Officer
Condensed Consolidated Statement of Comprehensive Income
For the six months ended 30 June 2023
Note | Six months ended 30 June 2023 Unaudited | Six months ended 30 June 2022 Unaudited | Year ended 31 December 2022 Audited | |
£'000 | £'000 | £'000 | ||
Revenue | 8 | 11,660 | 9,022 | 20,120 |
Cost of sales | (3,872) | (2,852) | (6,265) | |
Gross profit | 7,788 | 6,170 | 13,855 | |
Administrative expenses | (9,606) | (6,758) | (14,767) | |
Operating loss | (1,818) | (588) | (912) | |
Analysed as: | ||||
Adjusted EBITDA | 9 | 539 | 1,612 | |
Depreciation & amortisation | 11 | (1,451) | (1,109) | (2,232) |
Share based payment expense | (376) | (18) | (292) | |
Operating loss | (1,818) | (588) | (912) | |
Interest income | 91 | 17 | 81 | |
Loss before tax | (1,727) | (571) | (831) | |
Tax | 9 | 1,202 | 229 | 115 |
Total comprehensive loss for the period | (525) | (342) | (716) | |
Loss per share - basic (£) | 10 | (0.02) | (0.01) | (0.02) |
Loss per share - diluted (£) | 10 | (0.02) | (0.01) | (0.02)
|
Condensed Consolidated Balance Sheet
As at 30 June 2023
Note | 30 June 2023 Unaudited | 30 June 2022 Unaudited | 31 December 2022 Audited | |
£'000 | £'000 | £'000 | ||
Assets | ||||
Non-current assets | ||||
Goodwill | 511 | 511 | 511 | |
Development costs | 11 | 5,794 | 3,075 | 3,681 |
Right of use asset | 53 | - | 68 | |
Property, plant and equipment | 150 | 96 | 122 | |
Deferred tax asset | 1,626 | 420 | - | |
Total non-current assets | 8,134 | 4,102 | 4,382 | |
Current assets | ||||
Trade and other receivables | 12 | 2,355 | 2,632 | 2,618 |
Contract assets | 180 | 426 | 649 | |
Cash and cash equivalents | 5,850 | 8,310 | 8,492 | |
Total current assets | 8,385 | 11,368 | 11,759 | |
Total assets | 16,519 | 15,470 | 16,141 | |
Liabilities | ||||
Current liabilities | ||||
Trade payables | (1,047) | (331) | (680) | |
Contract liabilities | (3,096) | (2,797) | (2,583) | |
Lease liability | (54) | - | (68) | |
Accruals and other creditors | (913) | (737) | (977) | |
Deferred tax liabilities | - | - | (348) | |
Tax liabilities | (769) | (956) | (967) | |
Total current liabilities | (5,879) | (4,821) | (5,623) | |
Net current assets | 2,506 | 6,547 | 6,136 | |
Net assets | 10,640 | 10,649 | 10,518 | |
Equity | ||||
Share capital | 1,653 | 1,653 | 1,653 | |
Share premium account | 14,229 | 14,229 | 14,229 | |
Retained earnings | (3,120) | (2,221) | (2,595) | |
Share-based payment reserve | 1,867 | 977 | 1,221 | |
Capital redemption reserve | 115 | 115 | 115 | |
Merger reserve | (4,104) | (4,104) | (4,104) | |
Total equity | 10,640 | 10,649 | 10,518 |
Condensed Consolidated Statement of Cash Flows
For the six months ended 30 June 2023
Six months ended 30 June 2023 Unaudited | Six months ended 30 June 2022 Unaudited | Year ended 31 December 2022 Audited | ||
£'000 | £'000 | £'000 | ||
Cash flows from operating activities | ||||
Loss for the period | (525) | (342) | (716) | |
Adjusted for: | ||||
Depreciation & amortisation | 1,451 | 1,109 | 2,232 | |
Income tax received | 569 | 330 | 330 | |
Share based payment expense | 376 | 18 | 292 | |
Tax income recognised | (1,202) | (229) | (115) | |
Interest income | (91) | - | (81) | |
Movements in working capital: | ||||
(Increase) / decrease in trade and other receivables | 651 | (369) | 78 | |
Increase / (decrease) in trade and other payables | (384) | 2,009 | 2,364 | |
Net cashflow from operating activities | 845 | 2,527 | 4,384 | |
Cash flows from investing activities | ||||
Purchase of property, plant and equipment | (70) | (28) | (100) | |
Additions to intangible assets | (3,508) | (1,268) | (2,952) | |
Net cash used in investing activities | (3,578) | (1,296) | (3,052) | |
Cash flows from financing activities | ||||
Interest income | 91 | - | 81 | |
Net cash from financing activities | 91 | - | 81 | |
Net increase / (decrease) in cash and cash equivalents | (2,642) | 1,231 | 1,413 | |
Cash and cash equivalents at the beginning of the period | 8,492 | 7,079 | 7,079 | |
Cash and cash equivalents at the end of the period | 5,850 | 8,310 | 8,492 |
Condensed Consolidated Statement of Changes in Equity
For the six months ended 30 June 2023
Share Capital | Share Premium | Share Based Payment Reserve | Retained Eearnings | Capital Redemption Reserve | Merger reserve | Total Equity | |
Balance at 1 January 2022 | 1,653 | 14,229 | 959 | (1,879) | 115 | (4,104) | 10,973 |
Share based payments | - | - | 18 | - | - | - | 18 |
Total comprehensive income for the period | - | - | - | (342) | - | - | (342) |
As at 30 June 2022 | 1,653 | 14,229 | 977 | (2,221) | 115 | (4,104) | 10,649 |
Balance at 1 July 2022 | 1,653 | 14,229 | 977 | (2,221) | 115 | (4,104) | 10,649 |
Share based payments | - | - | 244 | - | - | - | 244 |
Total comprehensive income for the period | - | - | - | (374) | - | - | (374) |
As at 31 December 2022 | 1,653 | 14,229 | 1,221 | (2,595) | 115 | (4,104) | 10,519 |
Balance at 1 January 2023 | 1,653 | 14,229 | 1,221 | (2,595) | 115 | (4,104) | 10,519 |
Share based payments | - | - | 646 | - | - | - | 646 |
Total comprehensive income for the period | - | - | - | (525) | - | - | (525) |
As at 30 June 2023 | 1,653 | 14,229 | 1,867 | (3,120) | 115 | (4,104) | 10,640 |
2021
Half-year Results
21 September 2023
Strategic momentum and revenue growth of 29%
Full year revenue guidance of at least £34m
Kooth (AIM: KOO), a global leader in youth digital mental well-being, announces unaudited half year results for the six months ended 30 June 2023. All figures relate to this period unless otherwise stated.
Strategic and post period end highlights
- Transformational US contract win in California, $188m minimum value
- On track for California go-live in January 2024, notably with the Kooth mobile app and hires
- Number one provider of mental health access for children and young people to NHS England
- Significant uptake of Kooth in Pennsylvania pilot, providing access to c.100,000 school students
- Ongoing investment in business development, platform investment and US expansion
Financial Highlights
- Revenues up 29% to £11.7m (2022: £9.0m)
- Annual Recurring Revenue (ARR) up 16% to £21.4m (2022: £18.5m)
- Gross margin of 66.8% (2022: 68.4%)
- Adjusted EBITDA of £0.01m (2022: £0.5m) reflecting investment in US setup and business development
- Recurring Revenue from contracts 12 months or longer 94% (2022: 95%)
- Robust balance sheet; net cash of £5.9m plus successful gross fundraise of £10m post half-year end supports investment for long-term growth
Outlook
- Significant opportunity for Kooth in the US driven by the continued need from both US State governments and Medicaid payers to invest further in youth mental health
- For the UK, we expect the headwinds to remain, reflecting a focus on NHS cost saving and acute care backlog. Our focus remains on continuing to demonstrate the impact and savings that Kooth generates when commissioned in a region
- The Group remains confident of delivering revenue for the full year in line with our revised market guidance of no less than £34 million
- Our robust balance sheet enables us to invest to meet long-term, increasing demand for Kooth's services
Tim Barker, Chief Executive Officer of Kooth, said:
The first six months of 2023 have been a period of significant, and positive, change for Kooth. In March we announced our largest contract to date with the State of California which was finalised, post-period end, as a four year, $188m minimum value agreement. This marked Kooth's second major engagement in the US, alongside Pennsylvania, which was agreed in October 2022. During the period, and over the last 12 months, we have developed a significant operation in the United States as we look to capture the opportunity this major healthcare market brings. We look forward to leveraging our platform to increase the size of our business further and, more importantly, help improve mental health provision to as many young people as possible.
In the UK, we are not immune to the broader healthcare and economic environment, which sees commissioning across the NHS structure under stress as Integrated Care Systems prioritise a reduction in costs and tackling an acute mental healthcare backlog. In response, we have taken proactive steps to position ourselves to best respond to this environment, including developing new services to help tackle waiting lists.
I would like to thank our team for their work which has delivered transformational gains during the period and beyond as we look to leverage our position as a pioneer and innovator in digital mental healthcare to deliver the care needed to help tackle the growing crisis in global mental health.
Financial headlines
Six months ended 30 June 2023 | Six months ended 30 June 2022 | Change | |||
£'000 | £'000 | ||||
Revenue | |||||
Total revenue | 11,660 | 9,022 | +29.2% | ||
Annual Recurring Revenue | 21,376 | 18,483 | +15.7% | ||
Gross profit | 7,788 | 6,170 | +26.2% | ||
Gross margin | 66.8% | 68.4% | -2.3ppt | ||
Adjusted EBITDA | 9 | 539 | -98.3% | ||
Profit/(Loss) after tax for the period | (525) | (342) | -53.5% | ||
Cash generation | (2,642) | 1,231 | -314.6% | ||
Cash position | 5,850 | 8,310 | -29.6% | ||
Earnings per share (£) | (0.02) | (0.01) | -58.8% |
Enquiries Kooth plc | |
Tim Barker, CEO | |
Panmure Gordon, Nominated Adviser and Joint Broker | +44 (0) 20 7886 2500 |
Stifel Nicolaus Europe Limited, Joint Broker | +44 (0) 20 7710 7600 |
FTI Consulting |
About Kooth
Kooth (AIM:KOO) is a global leader in youth digital mental well-being. Our mission is to provide accessible and safe spaces for everyone to achieve better mental health. Our platform is clinically robust and accredited to provide a range of therapeutic support and interventions. All our services are predicated on easy access to make early intervention and prevention a reality.
Our three services are:
- Kooth: for children and young people
- Kooth: for adults
- Kooth Work: for frontline employees
Kooth is a fully safeguarded and pre-moderated community with a library of peer and professional created content, alongside access to experienced online counsellors. There are no thresholds for support and no waiting lists. Currently, Kooth sees more than 4,000 logins a day.
Kooth is the only digital mental health provider to hold a UK-wide accreditation from the British Association of Counselling and Psychotherapy (BACP) and according to NHS England data for 2021/22 is now the largest single access provider for mental health support for under 18s.
In 2021, Kooth began executing on its international expansion strategy, with an initial focus on the US market. This focus is due to the growing recognition of the importance of improving youth mental health in this key global healthcare market, with 1-in-6 people aged 6-17 experiencing a mental health disorder each year. Kooth's first major pilot contract in the US was signed in October 2022 with the State of Pennsylvania followed in July 2023 by a four-year contract to cover all six million 13-25 year-olds in the State of California.
Chief Executive's Review
Transformational strategic progress
With the award of a $188m four-year state-wide contract with California, the last six months demonstrate the significant opportunity for Kooth in the US as federal and state governments invest to transform youth mental health care.
As one of the work streams within the State of California's $4.7 billion youth masterplan, this investment arguably represents the world's most progressive initiative to improve youth mental health. This was evident at the September UN Congress General Assembly meeting, to which Kooth was invited. The key question is "how" rather than "if" this problem should be addressed. We remain deeply humbled to be entrusted with the opportunity to be at the forefront of supporting a landmark programme in the most populous state in the US, in what we believe will be a template for future governments and health care systems on how to safeguard the mental health of the next generation.
I have been very proud to see how our whole team has stepped up to the opportunity in California, with both the work undertaken to win the contract in March and then subsequently the shift into the delivery phase. This is hard but purposeful work across 30 workstreams spanning the development of our next-generation platform, marketing and promotion strategy, as well as building our workforce and organisational infrastructure.
We are on track for the launch of our contract in California in January 2024, with all major milestones and deliverables to date met:
- All our US VP-level hires are in place to support go-live, with talent joining the existing team from organisations including Headspace, Crisis Text Line and Oracle Cerner. Hiring for other roles is broadly on track, with Kooth's fiscal rigour, transparency and growth as a public company adding appeal to candidates, in a market where many VC backed organisations are shedding staff to reduce cash burn.
- A beta version of Kooth's new mobile app is live in two counties in California as part of a 'soft launch' test. Over the next few months we will be adding, iterating, and gathering feedback from young people to help optimise the app and experience ahead of go-live in January.
Beyond California, our pilot project in Pennsylvania reached a significant milestone with almost 100,000 students having access to Kooth in the school year, with 1 in 10 high school students having used the platform, an uptake which surpassed our expectations based on our UK experience.
In the UK, following on from the reorganisation of NHS England from 135 Care Commissioning Groups into 42 Integrated Care Systems ("ICSs"), the headwinds in commissioning remain challenging, as ICSs adapt to a new funding environment. In 2023/24, ICSs must deliver 6% in real term efficiency savings, at a time when there is a 16% annual increase in demand for mental health support.
While Kooth is an advocate for digital transformation to address this challenge, we have seen Commissioners faced with tough short-term decisions to divert funds into acute care and reduce investments elsewhere. This is a challenge being experienced across the industry and is not unique to Kooth. While we have seen an increase in contracts that expand upon renewal to 52% (2022: 32%), gains were offset by £2.4m of churn, a combination of funding unavailable to continue pilot contracts, reductions as contracts consolidated and increased competition. Overall net revenue retention was 100% (2022: 107%).
In response to the current commissioning environment, we have used our market leading position to take action and better position ourselves for the future:
- We have restructured our commercial team with a focus on adding seniority and stakeholder management to engage NHS commissioners and Integrated Care Boards ("ICBs").
- We have grown and invested further in both our commissioner-marketing and user-marketing teams.
- We have launched an Integrated Digital Pathway ("IDP") service to help reduce pressure on CAMHS and IAPT services by providing support to individuals while on a waiting list, with the goal of discharging individuals if appropriate, or preventing further deterioration while awaiting treatment. We are currently piloting this unique service in two regions.
Management believes that these actions will help Kooth respond to the long-term opportunity that remains in helping ICSs to deliver on their vision to transform healthcare services, focus on prevention, and support the population health of their regions.
Kooth Adult (UK)
As a result of the pressures described above, our Kooth Adult services have been impacted more so than our service for children and young people, with ARR standing at £2.6m (FY2022: £3.0m). This is primarily due to newer contracts not being continued after a first year of piloting, as local commissioners seek to make budget available for acute service delivery.
Kooth Children and Young People (UK)
In contrast to the challenging commissioning environment in England, Kooth continues to expand in Scotland with new commissions in East Ayrshire, Inverclyde and North Lanarkshire.
From a product/service perspective, we anticipate strong interest from both children and young people, and commissioners in learning how our enhanced platform could better serve their needs. When California is live we intend to use this showcase to better demonstrate the step change that is possible through digital transformation in delivering a population-wide mental health strategy.
Current trading and outlook
Kooth will continue to invest significantly in its technology platform, systems and talent to deliver on our next generation platform for California. We will then bring these innovations to all US and UK customers to deliver enhanced support for all.
We continue to see both US State governments and Medicaid payers recognise the need to invest further in youth mental health and are optimistic about the significant opportunity that Kooth has in the US. For the UK, we expect the current situation to remain for some time, with our focus being on continuing to demonstrate the impact and savings that result when Kooth is commissioned in a region.
The Group remains confident of delivering revenue for the full year in line with our revised market guidance of no less than £34 million.
Our robust balance sheet enables us to invest to meet long-term, increasing demand for Kooth's services. We will continue this investment in our talent and technology to enable us to scale up to tackle what is one of the world's biggest challenges.
Tim Barker
Chief Executive
Chief Financial Officer's review
Kooth delivered a strong performance in the period supported by an increase across revenue and annual recurring revenue, a good gross margin as well as continuing to invest in our platform and the business for the half year ended 30 June 2023 as compared to the six months ended 30 June 2022.
Key Performance Indicators
Total Revenue
£11.7m | £9.0m | £8.0m | £5.9m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
As we continue to invest in and grow our business, revenue growth demonstrates the progress we are making.
Annual Recurring Revenue
£21.4m | £18.5m | £16.6m | £13.1m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Annual Recurring Revenue ("ARR") is the annualised revenue of customers engaged or closed as at the period end and is an indication of the upcoming annual value of the recurring revenue. This is used by management to monitor the long term revenue growth of the business.
Gross Margin
66.8% | 68.4% | 69.4% | 69.6% |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Gross Profit as a percentage of revenue. Direct costs are the costs of our practitioners directly involved in the delivery of our services.
Adjusted EBITDA
£0.0m | £0.5m | £1.1m | £0.5m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Earnings before interest, tax, depreciation and amortisation in the period, adjusted for share based payments and exceptional costs. This metric provides a more comparable indication of the Group's core business performance by removing the impact of non-trading items that are reported separately.
Number of customers
149 | 141 | 142 | 104 |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
The total number of live contracts with customers. As the NHS finalised the consolidation from 135 Clinical Commissioning Groups to 42 Integrated Care Systems in the last year, we are seeing a shift to fewer, larger contracts spanning the whole population within an ICS region.
Service user logins
1.4m | 1.4m | 1.2m | 1.0m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
The number of logins to Kooth from users, demonstrating uptake of our service.
Revenue
Revenue increased by 29% to £11.7m (2022 H1: £9.0m), Annual Recurring Revenue grew by 16% to £21.4m (2022 H1: £18.5m), with ten new contracts won in the first half of 2023. The revenue increase is predominantly attributable to US revenue of £1.8m in H1 2023 (2022 H1: £Nil) where we now have three contracts and included non-recurring revenue from the state of California for one-off research and pilot study work. This led to a slight decrease in recurring revenue (which comprises income invoiced for services that are repeatable, consumed and delivered on a monthly basis over the term of a customer contract) as a percentage of overall revenue from 95% to 94%.
Churn was 13% giving net revenue retention (measured by the total value of on-going ARR at the period-end from clients in place 12 months earlier as a percentage of the opening ARR from those clients) for the period to 30 June 2023 of 100%. This has decreased from 107% recorded in H1 2022 which is a result of an increase in churn within our English contracts where we are seeing the impact of funding being redirected to more acute care, a resizing of pilot adult contracts and a slowdown in uplifts as well as budgetary pressures as the NHS transitioned from a CCG to ICS structure.
Gross Profit
Gross Profit increased 26% from £6.2m to £7.8m with gross margin slightly down at 66.8% (2022 H1: 68.4%). Direct costs are the costs of the practitioners directly involved in the delivery of our services, a total of 251 at the period-end (2022 H1: 213 heads). Gross margin dropped in the UK as salary increases at the start of 2023 reflected inflationary pressures and we took a decision to enhance contract performance for the protection of longer-term growth. These were partially offset by the end of the 1.25% Health and Social Care Levy and a positive mix impact as our new US contracts ramped up.
Adjusted EBITDA
Adjusted EBITDA in the period decreased from £0.5m to £0.01m with an increased gross profit offset by a 38% increase in administrative expenses (excluding amortisation, depreciation and share based payments). Whilst UK costs increased in line with salary inflation and revenue growth requiring increased promotion spend, the majority of the increase related to the build out of the US teams supporting our Pennsylvania and California contracts.
The total charge for share based payments in the period was £0.4m (2022 H1: £0.02m). The increase reflects the annual issue of three year grants to all staff and a credit in 2022 following a reassessment of those grants subject to performance criteria. Depreciation and amortisation increased to £1.5m (2022 H1 £1.1m) as capital expenditure commenced on the US platform build.
Taxation
The overall tax credit for the six months ended 30 June 2023 (£1.2m) and 2022 (£0.2m) relate to Research and Development expenditure credits in addition to the movement in the deferred tax asset with the increase reflecting greater R&D spend and an increase in the effective tax rate on losses.
Loss after tax
The Group loss after tax for the period was £0.5m (2022 H1: £0.3m).
Balance Sheet
The strength of the Group's balance sheet with net assets of £10.6m (30 June 2022: £10.6m), plus a successful gross fundraise of £10m post half year end, and high levels of recurring revenue provide the Group with financial strength to execute on its investment strategy which continues to focus on US business development and platform investment.
Cash flow and financing
Cash outflow during the six months was £2.6m (2022 H1: £1.2m inflow). The focus on US platform investment gave rise to capital expenditure of £3.5m (2022 H1: £1.3m), offset by cash inflows from operating activities of £0.8m including receipt of an R&D government tax credit of £0.6m giving a net cash position at 30 June 2023 of £5.9m (2022 H1: £8.3m).
The Group remains debt free.
Forward-looking statements
Certain statements in this half year report are forward looking. Although the Group believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. Because these statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements.
Dividends
The Group's intention in the short to medium term is to invest in order to deliver capital growth for shareholders. The Board has not recommended an interim dividend payment in respect of the six months ended 30 June 2023 (2022: £nil) and does not anticipate recommending a dividend within the next year but may do so in future years.
Sanjay Jawa
Chief Financial Officer
Condensed Consolidated Statement of Comprehensive Income
For the six months ended 30 June 2023
Note | Six months ended 30 June 2023 Unaudited | Six months ended 30 June 2022 Unaudited | Year ended 31 December 2022 Audited | |
£'000 | £'000 | £'000 | ||
Revenue | 8 | 11,660 | 9,022 | 20,120 |
Cost of sales | (3,872) | (2,852) | (6,265) | |
Gross profit | 7,788 | 6,170 | 13,855 | |
Administrative expenses | (9,606) | (6,758) | (14,767) | |
Operating loss | (1,818) | (588) | (912) | |
Analysed as: | ||||
Adjusted EBITDA | 9 | 539 | 1,612 | |
Depreciation & amortisation | 11 | (1,451) | (1,109) | (2,232) |
Share based payment expense | (376) | (18) | (292) | |
Operating loss | (1,818) | (588) | (912) | |
Interest income | 91 | 17 | 81 | |
Loss before tax | (1,727) | (571) | (831) | |
Tax | 9 | 1,202 | 229 | 115 |
Total comprehensive loss for the period | (525) | (342) | (716) | |
Loss per share - basic (£) | 10 | (0.02) | (0.01) | (0.02) |
Loss per share - diluted (£) | 10 | (0.02) | (0.01) | (0.02)
|
Condensed Consolidated Balance Sheet
As at 30 June 2023
Note | 30 June 2023 Unaudited | 30 June 2022 Unaudited | 31 December 2022 Audited | |
£'000 | £'000 | £'000 | ||
Assets | ||||
Non-current assets | ||||
Goodwill | 511 | 511 | 511 | |
Development costs | 11 | 5,794 | 3,075 | 3,681 |
Right of use asset | 53 | - | 68 | |
Property, plant and equipment | 150 | 96 | 122 | |
Deferred tax asset | 1,626 | 420 | - | |
Total non-current assets | 8,134 | 4,102 | 4,382 | |
Current assets | ||||
Trade and other receivables | 12 | 2,355 | 2,632 | 2,618 |
Contract assets | 180 | 426 | 649 | |
Cash and cash equivalents | 5,850 | 8,310 | 8,492 | |
Total current assets | 8,385 | 11,368 | 11,759 | |
Total assets | 16,519 | 15,470 | 16,141 | |
Liabilities | ||||
Current liabilities | ||||
Trade payables | (1,047) | (331) | (680) | |
Contract liabilities | (3,096) | (2,797) | (2,583) | |
Lease liability | (54) | - | (68) | |
Accruals and other creditors | (913) | (737) | (977) | |
Deferred tax liabilities | - | - | (348) | |
Tax liabilities | (769) | (956) | (967) | |
Total current liabilities | (5,879) | (4,821) | (5,623) | |
Net current assets | 2,506 | 6,547 | 6,136 | |
Net assets | 10,640 | 10,649 | 10,518 | |
Equity | ||||
Share capital | 1,653 | 1,653 | 1,653 | |
Share premium account | 14,229 | 14,229 | 14,229 | |
Retained earnings | (3,120) | (2,221) | (2,595) | |
Share-based payment reserve | 1,867 | 977 | 1,221 | |
Capital redemption reserve | 115 | 115 | 115 | |
Merger reserve | (4,104) | (4,104) | (4,104) | |
Total equity | 10,640 | 10,649 | 10,518 |
Condensed Consolidated Statement of Cash Flows
For the six months ended 30 June 2023
Six months ended 30 June 2023 Unaudited | Six months ended 30 June 2022 Unaudited | Year ended 31 December 2022 Audited | ||
£'000 | £'000 | £'000 | ||
Cash flows from operating activities | ||||
Loss for the period | (525) | (342) | (716) | |
Adjusted for: | ||||
Depreciation & amortisation | 1,451 | 1,109 | 2,232 | |
Income tax received | 569 | 330 | 330 | |
Share based payment expense | 376 | 18 | 292 | |
Tax income recognised | (1,202) | (229) | (115) | |
Interest income | (91) | - | (81) | |
Movements in working capital: | ||||
(Increase) / decrease in trade and other receivables | 651 | (369) | 78 | |
Increase / (decrease) in trade and other payables | (384) | 2,009 | 2,364 | |
Net cashflow from operating activities | 845 | 2,527 | 4,384 | |
Cash flows from investing activities | ||||
Purchase of property, plant and equipment | (70) | (28) | (100) | |
Additions to intangible assets | (3,508) | (1,268) | (2,952) | |
Net cash used in investing activities | (3,578) | (1,296) | (3,052) | |
Cash flows from financing activities | ||||
Interest income | 91 | - | 81 | |
Net cash from financing activities | 91 | - | 81 | |
Net increase / (decrease) in cash and cash equivalents | (2,642) | 1,231 | 1,413 | |
Cash and cash equivalents at the beginning of the period | 8,492 | 7,079 | 7,079 | |
Cash and cash equivalents at the end of the period | 5,850 | 8,310 | 8,492 |
Condensed Consolidated Statement of Changes in Equity
For the six months ended 30 June 2023
Share Capital | Share Premium | Share Based Payment Reserve | Retained Eearnings | Capital Redemption Reserve | Merger reserve | Total Equity | |
Balance at 1 January 2022 | 1,653 | 14,229 | 959 | (1,879) | 115 | (4,104) | 10,973 |
Share based payments | - | - | 18 | - | - | - | 18 |
Total comprehensive income for the period | - | - | - | (342) | - | - | (342) |
As at 30 June 2022 | 1,653 | 14,229 | 977 | (2,221) | 115 | (4,104) | 10,649 |
Balance at 1 July 2022 | 1,653 | 14,229 | 977 | (2,221) | 115 | (4,104) | 10,649 |
Share based payments | - | - | 244 | - | - | - | 244 |
Total comprehensive income for the period | - | - | - | (374) | - | - | (374) |
As at 31 December 2022 | 1,653 | 14,229 | 1,221 | (2,595) | 115 | (4,104) | 10,519 |
Balance at 1 January 2023 | 1,653 | 14,229 | 1,221 | (2,595) | 115 | (4,104) | 10,519 |
Share based payments | - | - | 646 | - | - | - | 646 |
Total comprehensive income for the period | - | - | - | (525) | - | - | (525) |
As at 30 June 2023 | 1,653 | 14,229 | 1,867 | (3,120) | 115 | (4,104) | 10,640 |
2020
Half-year Results
21 September 2023
Strategic momentum and revenue growth of 29%
Full year revenue guidance of at least £34m
Kooth (AIM: KOO), a global leader in youth digital mental well-being, announces unaudited half year results for the six months ended 30 June 2023. All figures relate to this period unless otherwise stated.
Strategic and post period end highlights
- Transformational US contract win in California, $188m minimum value
- On track for California go-live in January 2024, notably with the Kooth mobile app and hires
- Number one provider of mental health access for children and young people to NHS England
- Significant uptake of Kooth in Pennsylvania pilot, providing access to c.100,000 school students
- Ongoing investment in business development, platform investment and US expansion
Financial Highlights
- Revenues up 29% to £11.7m (2022: £9.0m)
- Annual Recurring Revenue (ARR) up 16% to £21.4m (2022: £18.5m)
- Gross margin of 66.8% (2022: 68.4%)
- Adjusted EBITDA of £0.01m (2022: £0.5m) reflecting investment in US setup and business development
- Recurring Revenue from contracts 12 months or longer 94% (2022: 95%)
- Robust balance sheet; net cash of £5.9m plus successful gross fundraise of £10m post half-year end supports investment for long-term growth
Outlook
- Significant opportunity for Kooth in the US driven by the continued need from both US State governments and Medicaid payers to invest further in youth mental health
- For the UK, we expect the headwinds to remain, reflecting a focus on NHS cost saving and acute care backlog. Our focus remains on continuing to demonstrate the impact and savings that Kooth generates when commissioned in a region
- The Group remains confident of delivering revenue for the full year in line with our revised market guidance of no less than £34 million
- Our robust balance sheet enables us to invest to meet long-term, increasing demand for Kooth's services
Tim Barker, Chief Executive Officer of Kooth, said:
The first six months of 2023 have been a period of significant, and positive, change for Kooth. In March we announced our largest contract to date with the State of California which was finalised, post-period end, as a four year, $188m minimum value agreement. This marked Kooth's second major engagement in the US, alongside Pennsylvania, which was agreed in October 2022. During the period, and over the last 12 months, we have developed a significant operation in the United States as we look to capture the opportunity this major healthcare market brings. We look forward to leveraging our platform to increase the size of our business further and, more importantly, help improve mental health provision to as many young people as possible.
In the UK, we are not immune to the broader healthcare and economic environment, which sees commissioning across the NHS structure under stress as Integrated Care Systems prioritise a reduction in costs and tackling an acute mental healthcare backlog. In response, we have taken proactive steps to position ourselves to best respond to this environment, including developing new services to help tackle waiting lists.
I would like to thank our team for their work which has delivered transformational gains during the period and beyond as we look to leverage our position as a pioneer and innovator in digital mental healthcare to deliver the care needed to help tackle the growing crisis in global mental health.
Financial headlines
Six months ended 30 June 2023 | Six months ended 30 June 2022 | Change | |||
£'000 | £'000 | ||||
Revenue | |||||
Total revenue | 11,660 | 9,022 | +29.2% | ||
Annual Recurring Revenue | 21,376 | 18,483 | +15.7% | ||
Gross profit | 7,788 | 6,170 | +26.2% | ||
Gross margin | 66.8% | 68.4% | -2.3ppt | ||
Adjusted EBITDA | 9 | 539 | -98.3% | ||
Profit/(Loss) after tax for the period | (525) | (342) | -53.5% | ||
Cash generation | (2,642) | 1,231 | -314.6% | ||
Cash position | 5,850 | 8,310 | -29.6% | ||
Earnings per share (£) | (0.02) | (0.01) | -58.8% |
Enquiries Kooth plc | |
Tim Barker, CEO | |
Panmure Gordon, Nominated Adviser and Joint Broker | +44 (0) 20 7886 2500 |
Stifel Nicolaus Europe Limited, Joint Broker | +44 (0) 20 7710 7600 |
FTI Consulting |
About Kooth
Kooth (AIM:KOO) is a global leader in youth digital mental well-being. Our mission is to provide accessible and safe spaces for everyone to achieve better mental health. Our platform is clinically robust and accredited to provide a range of therapeutic support and interventions. All our services are predicated on easy access to make early intervention and prevention a reality.
Our three services are:
- Kooth: for children and young people
- Kooth: for adults
- Kooth Work: for frontline employees
Kooth is a fully safeguarded and pre-moderated community with a library of peer and professional created content, alongside access to experienced online counsellors. There are no thresholds for support and no waiting lists. Currently, Kooth sees more than 4,000 logins a day.
Kooth is the only digital mental health provider to hold a UK-wide accreditation from the British Association of Counselling and Psychotherapy (BACP) and according to NHS England data for 2021/22 is now the largest single access provider for mental health support for under 18s.
In 2021, Kooth began executing on its international expansion strategy, with an initial focus on the US market. This focus is due to the growing recognition of the importance of improving youth mental health in this key global healthcare market, with 1-in-6 people aged 6-17 experiencing a mental health disorder each year. Kooth's first major pilot contract in the US was signed in October 2022 with the State of Pennsylvania followed in July 2023 by a four-year contract to cover all six million 13-25 year-olds in the State of California.
Chief Executive's Review
Transformational strategic progress
With the award of a $188m four-year state-wide contract with California, the last six months demonstrate the significant opportunity for Kooth in the US as federal and state governments invest to transform youth mental health care.
As one of the work streams within the State of California's $4.7 billion youth masterplan, this investment arguably represents the world's most progressive initiative to improve youth mental health. This was evident at the September UN Congress General Assembly meeting, to which Kooth was invited. The key question is "how" rather than "if" this problem should be addressed. We remain deeply humbled to be entrusted with the opportunity to be at the forefront of supporting a landmark programme in the most populous state in the US, in what we believe will be a template for future governments and health care systems on how to safeguard the mental health of the next generation.
I have been very proud to see how our whole team has stepped up to the opportunity in California, with both the work undertaken to win the contract in March and then subsequently the shift into the delivery phase. This is hard but purposeful work across 30 workstreams spanning the development of our next-generation platform, marketing and promotion strategy, as well as building our workforce and organisational infrastructure.
We are on track for the launch of our contract in California in January 2024, with all major milestones and deliverables to date met:
- All our US VP-level hires are in place to support go-live, with talent joining the existing team from organisations including Headspace, Crisis Text Line and Oracle Cerner. Hiring for other roles is broadly on track, with Kooth's fiscal rigour, transparency and growth as a public company adding appeal to candidates, in a market where many VC backed organisations are shedding staff to reduce cash burn.
- A beta version of Kooth's new mobile app is live in two counties in California as part of a 'soft launch' test. Over the next few months we will be adding, iterating, and gathering feedback from young people to help optimise the app and experience ahead of go-live in January.
Beyond California, our pilot project in Pennsylvania reached a significant milestone with almost 100,000 students having access to Kooth in the school year, with 1 in 10 high school students having used the platform, an uptake which surpassed our expectations based on our UK experience.
In the UK, following on from the reorganisation of NHS England from 135 Care Commissioning Groups into 42 Integrated Care Systems ("ICSs"), the headwinds in commissioning remain challenging, as ICSs adapt to a new funding environment. In 2023/24, ICSs must deliver 6% in real term efficiency savings, at a time when there is a 16% annual increase in demand for mental health support.
While Kooth is an advocate for digital transformation to address this challenge, we have seen Commissioners faced with tough short-term decisions to divert funds into acute care and reduce investments elsewhere. This is a challenge being experienced across the industry and is not unique to Kooth. While we have seen an increase in contracts that expand upon renewal to 52% (2022: 32%), gains were offset by £2.4m of churn, a combination of funding unavailable to continue pilot contracts, reductions as contracts consolidated and increased competition. Overall net revenue retention was 100% (2022: 107%).
In response to the current commissioning environment, we have used our market leading position to take action and better position ourselves for the future:
- We have restructured our commercial team with a focus on adding seniority and stakeholder management to engage NHS commissioners and Integrated Care Boards ("ICBs").
- We have grown and invested further in both our commissioner-marketing and user-marketing teams.
- We have launched an Integrated Digital Pathway ("IDP") service to help reduce pressure on CAMHS and IAPT services by providing support to individuals while on a waiting list, with the goal of discharging individuals if appropriate, or preventing further deterioration while awaiting treatment. We are currently piloting this unique service in two regions.
Management believes that these actions will help Kooth respond to the long-term opportunity that remains in helping ICSs to deliver on their vision to transform healthcare services, focus on prevention, and support the population health of their regions.
Kooth Adult (UK)
As a result of the pressures described above, our Kooth Adult services have been impacted more so than our service for children and young people, with ARR standing at £2.6m (FY2022: £3.0m). This is primarily due to newer contracts not being continued after a first year of piloting, as local commissioners seek to make budget available for acute service delivery.
Kooth Children and Young People (UK)
In contrast to the challenging commissioning environment in England, Kooth continues to expand in Scotland with new commissions in East Ayrshire, Inverclyde and North Lanarkshire.
From a product/service perspective, we anticipate strong interest from both children and young people, and commissioners in learning how our enhanced platform could better serve their needs. When California is live we intend to use this showcase to better demonstrate the step change that is possible through digital transformation in delivering a population-wide mental health strategy.
Current trading and outlook
Kooth will continue to invest significantly in its technology platform, systems and talent to deliver on our next generation platform for California. We will then bring these innovations to all US and UK customers to deliver enhanced support for all.
We continue to see both US State governments and Medicaid payers recognise the need to invest further in youth mental health and are optimistic about the significant opportunity that Kooth has in the US. For the UK, we expect the current situation to remain for some time, with our focus being on continuing to demonstrate the impact and savings that result when Kooth is commissioned in a region.
The Group remains confident of delivering revenue for the full year in line with our revised market guidance of no less than £34 million.
Our robust balance sheet enables us to invest to meet long-term, increasing demand for Kooth's services. We will continue this investment in our talent and technology to enable us to scale up to tackle what is one of the world's biggest challenges.
Tim Barker
Chief Executive
Chief Financial Officer's review
Kooth delivered a strong performance in the period supported by an increase across revenue and annual recurring revenue, a good gross margin as well as continuing to invest in our platform and the business for the half year ended 30 June 2023 as compared to the six months ended 30 June 2022.
Key Performance Indicators
Total Revenue
£11.7m | £9.0m | £8.0m | £5.9m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
As we continue to invest in and grow our business, revenue growth demonstrates the progress we are making.
Annual Recurring Revenue
£21.4m | £18.5m | £16.6m | £13.1m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Annual Recurring Revenue ("ARR") is the annualised revenue of customers engaged or closed as at the period end and is an indication of the upcoming annual value of the recurring revenue. This is used by management to monitor the long term revenue growth of the business.
Gross Margin
66.8% | 68.4% | 69.4% | 69.6% |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Gross Profit as a percentage of revenue. Direct costs are the costs of our practitioners directly involved in the delivery of our services.
Adjusted EBITDA
£0.0m | £0.5m | £1.1m | £0.5m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
Earnings before interest, tax, depreciation and amortisation in the period, adjusted for share based payments and exceptional costs. This metric provides a more comparable indication of the Group's core business performance by removing the impact of non-trading items that are reported separately.
Number of customers
149 | 141 | 142 | 104 |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
The total number of live contracts with customers. As the NHS finalised the consolidation from 135 Clinical Commissioning Groups to 42 Integrated Care Systems in the last year, we are seeing a shift to fewer, larger contracts spanning the whole population within an ICS region.
Service user logins
1.4m | 1.4m | 1.2m | 1.0m |
H1 2023 | H1 2022 | H1 2021 | H1 2020 |
The number of logins to Kooth from users, demonstrating uptake of our service.
Revenue
Revenue increased by 29% to £11.7m (2022 H1: £9.0m), Annual Recurring Revenue grew by 16% to £21.4m (2022 H1: £18.5m), with ten new contracts won in the first half of 2023. The revenue increase is predominantly attributable to US revenue of £1.8m in H1 2023 (2022 H1: £Nil) where we now have three contracts and included non-recurring revenue from the state of California for one-off research and pilot study work. This led to a slight decrease in recurring revenue (which comprises income invoiced for services that are repeatable, consumed and delivered on a monthly basis over the term of a customer contract) as a percentage of overall revenue from 95% to 94%.
Churn was 13% giving net revenue retention (measured by the total value of on-going ARR at the period-end from clients in place 12 months earlier as a percentage of the opening ARR from those clients) for the period to 30 June 2023 of 100%. This has decreased from 107% recorded in H1 2022 which is a result of an increase in churn within our English contracts where we are seeing the impact of funding being redirected to more acute care, a resizing of pilot adult contracts and a slowdown in uplifts as well as budgetary pressures as the NHS transitioned from a CCG to ICS structure.
Gross Profit
Gross Profit increased 26% from £6.2m to £7.8m with gross margin slightly down at 66.8% (2022 H1: 68.4%). Direct costs are the costs of the practitioners directly involved in the delivery of our services, a total of 251 at the period-end (2022 H1: 213 heads). Gross margin dropped in the UK as salary increases at the start of 2023 reflected inflationary pressures and we took a decision to enhance contract performance for the protection of longer-term growth. These were partially offset by the end of the 1.25% Health and Social Care Levy and a positive mix impact as our new US contracts ramped up.
Adjusted EBITDA
Adjusted EBITDA in the period decreased from £0.5m to £0.01m with an increased gross profit offset by a 38% increase in administrative expenses (excluding amortisation, depreciation and share based payments). Whilst UK costs increased in line with salary inflation and revenue growth requiring increased promotion spend, the majority of the increase related to the build out of the US teams supporting our Pennsylvania and California contracts.
The total charge for share based payments in the period was £0.4m (2022 H1: £0.02m). The increase reflects the annual issue of three year grants to all staff and a credit in 2022 following a reassessment of those grants subject to performance criteria. Depreciation and amortisation increased to £1.5m (2022 H1 £1.1m) as capital expenditure commenced on the US platform build.
Taxation
The overall tax credit for the six months ended 30 June 2023 (£1.2m) and 2022 (£0.2m) relate to Research and Development expenditure credits in addition to the movement in the deferred tax asset with the increase reflecting greater R&D spend and an increase in the effective tax rate on losses.
Loss after tax
The Group loss after tax for the period was £0.5m (2022 H1: £0.3m).
Balance Sheet
The strength of the Group's balance sheet with net assets of £10.6m (30 June 2022: £10.6m), plus a successful gross fundraise of £10m post half year end, and high levels of recurring revenue provide the Group with financial strength to execute on its investment strategy which continues to focus on US business development and platform investment.
Cash flow and financing
Cash outflow during the six months was £2.6m (2022 H1: £1.2m inflow). The focus on US platform investment gave rise to capital expenditure of £3.5m (2022 H1: £1.3m), offset by cash inflows from operating activities of £0.8m including receipt of an R&D government tax credit of £0.6m giving a net cash position at 30 June 2023 of £5.9m (2022 H1: £8.3m).
The Group remains debt free.
Forward-looking statements
Certain statements in this half year report are forward looking. Although the Group believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. Because these statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements.
Dividends
The Group's intention in the short to medium term is to invest in order to deliver capital growth for shareholders. The Board has not recommended an interim dividend payment in respect of the six months ended 30 June 2023 (2022: £nil) and does not anticipate recommending a dividend within the next year but may do so in future years.
Sanjay Jawa
Chief Financial Officer
Condensed Consolidated Statement of Comprehensive Income
For the six months ended 30 June 2023
Note | Six months ended 30 June 2023 Unaudited | Six months ended 30 June 2022 Unaudited | Year ended 31 December 2022 Audited | |
£'000 | £'000 | £'000 | ||
Revenue | 8 | 11,660 | 9,022 | 20,120 |
Cost of sales | (3,872) | (2,852) | (6,265) | |
Gross profit | 7,788 | 6,170 | 13,855 | |
Administrative expenses | (9,606) | (6,758) | (14,767) | |
Operating loss | (1,818) | (588) | (912) | |
Analysed as: | ||||
Adjusted EBITDA | 9 | 539 | 1,612 | |
Depreciation & amortisation | 11 | (1,451) | (1,109) | (2,232) |
Share based payment expense | (376) | (18) | (292) | |
Operating loss | (1,818) | (588) | (912) | |
Interest income | 91 | 17 | 81 | |
Loss before tax | (1,727) | (571) | (831) | |
Tax | 9 | 1,202 | 229 | 115 |
Total comprehensive loss for the period | (525) | (342) | (716) | |
Loss per share - basic (£) | 10 | (0.02) | (0.01) | (0.02) |
Loss per share - diluted (£) | 10 | (0.02) | (0.01) | (0.02)
|
Condensed Consolidated Balance Sheet
As at 30 June 2023
Note | 30 June 2023 Unaudited | 30 June 2022 Unaudited | 31 December 2022 Audited | |
£'000 | £'000 | £'000 | ||
Assets | ||||
Non-current assets | ||||
Goodwill | 511 | 511 | 511 | |
Development costs | 11 | 5,794 | 3,075 | 3,681 |
Right of use asset | 53 | - | 68 | |
Property, plant and equipment | 150 | 96 | 122 | |
Deferred tax asset | 1,626 | 420 | - | |
Total non-current assets | 8,134 | 4,102 | 4,382 | |
Current assets | ||||
Trade and other receivables | 12 | 2,355 | 2,632 | 2,618 |
Contract assets | 180 | 426 | 649 | |
Cash and cash equivalents | 5,850 | 8,310 | 8,492 | |
Total current assets | 8,385 | 11,368 | 11,759 | |
Total assets | 16,519 | 15,470 | 16,141 | |
Liabilities | ||||
Current liabilities | ||||
Trade payables | (1,047) | (331) | (680) | |
Contract liabilities | (3,096) | (2,797) | (2,583) | |
Lease liability | (54) | - | (68) | |
Accruals and other creditors | (913) | (737) | (977) | |
Deferred tax liabilities | - | - | (348) | |
Tax liabilities | (769) | (956) | (967) | |
Total current liabilities | (5,879) | (4,821) | (5,623) | |
Net current assets | 2,506 | 6,547 | 6,136 | |
Net assets | 10,640 | 10,649 | 10,518 | |
Equity | ||||
Share capital | 1,653 | 1,653 | 1,653 | |
Share premium account | 14,229 | 14,229 | 14,229 | |
Retained earnings | (3,120) | (2,221) | (2,595) | |
Share-based payment reserve | 1,867 | 977 | 1,221 | |
Capital redemption reserve | 115 | 115 | 115 | |
Merger reserve | (4,104) | (4,104) | (4,104) | |
Total equity | 10,640 | 10,649 | 10,518 |
Condensed Consolidated Statement of Cash Flows
For the six months ended 30 June 2023
Six months ended 30 June 2023 Unaudited | Six months ended 30 June 2022 Unaudited | Year ended 31 December 2022 Audited | ||
£'000 | £'000 | £'000 | ||
Cash flows from operating activities | ||||
Loss for the period | (525) | (342) | (716) | |
Adjusted for: | ||||
Depreciation & amortisation | 1,451 | 1,109 | 2,232 | |
Income tax received | 569 | 330 | 330 | |
Share based payment expense | 376 | 18 | 292 | |
Tax income recognised | (1,202) | (229) | (115) | |
Interest income | (91) | - | (81) | |
Movements in working capital: | ||||
(Increase) / decrease in trade and other receivables | 651 | (369) | 78 | |
Increase / (decrease) in trade and other payables | (384) | 2,009 | 2,364 | |
Net cashflow from operating activities | 845 | 2,527 | 4,384 | |
Cash flows from investing activities | ||||
Purchase of property, plant and equipment | (70) | (28) | (100) | |
Additions to intangible assets | (3,508) | (1,268) | (2,952) | |
Net cash used in investing activities | (3,578) | (1,296) | (3,052) | |
Cash flows from financing activities | ||||
Interest income | 91 | - | 81 | |
Net cash from financing activities | 91 | - | 81 | |
Net increase / (decrease) in cash and cash equivalents | (2,642) | 1,231 | 1,413 | |
Cash and cash equivalents at the beginning of the period | 8,492 | 7,079 | 7,079 | |
Cash and cash equivalents at the end of the period | 5,850 | 8,310 | 8,492 |
Condensed Consolidated Statement of Changes in Equity
For the six months ended 30 June 2023
Share Capital | Share Premium | Share Based Payment Reserve | Retained Eearnings | Capital Redemption Reserve | Merger reserve | Total Equity | |
Balance at 1 January 2022 | 1,653 | 14,229 | 959 | (1,879) | 115 | (4,104) | 10,973 |
Share based payments | - | - | 18 | - | - | - | 18 |
Total comprehensive income for the period | - | - | - | (342) | - | - | (342) |
As at 30 June 2022 | 1,653 | 14,229 | 977 | (2,221) | 115 | (4,104) | 10,649 |
Balance at 1 July 2022 | 1,653 | 14,229 | 977 | (2,221) | 115 | (4,104) | 10,649 |
Share based payments | - | - | 244 | - | - | - | 244 |
Total comprehensive income for the period | - | - | - | (374) | - | - | (374) |
As at 31 December 2022 | 1,653 | 14,229 | 1,221 | (2,595) | 115 | (4,104) | 10,519 |
Balance at 1 January 2023 | 1,653 | 14,229 | 1,221 | (2,595) | 115 | (4,104) | 10,519 |
Share based payments | - | - | 646 | - | - | - | 646 |
Total comprehensive income for the period | - | - | - | (525) | - | - | (525) |
As at 30 June 2023 | 1,653 | 14,229 | 1,867 | (3,120) | 115 | (4,104) | 10,640 |